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resumo A caquexia associada ao cancro (CC, do inglês: cancer cachexia) é 
uma síndrome metabólica que afeta mais do que 50% dos pacientes 
com cancro e, para a qual, atualmente, não existe tratamento. Uma 
das características principais desta síndrome é a perda involuntária e 
massiva de massa muscular, sendo esta associada a um mau 
prognóstico. A ativação de vias catabólicas e a presença de um 
estado inflamatório são responsáveis pelo processo de catabolismo. 
Assim, as intervenções terapêuticas direcionadas para a massa 
muscular ou para as vias ativadas pelo processo inflamatório serão, 
provavelmente, efetivas na diminuição dos efeitos devastadores da 
caquexia. Para além dos efeitos negativos do cancro na massa 
muscular, a quimioterapia tem vindo, também, a ser relacionada com 
o desenvolvimento e exacerbação desta síndrome. Infelizmente, os 
mecanismos responsáveis pelo catabolismo muscular induzido pela 
quimioterapia são pouco conhecidos e os estudos que têm sido 
realizados para a compreensão dos mesmos são escassos. Desta 
forma, na presente dissertação foi investigado, em animais saudáveis 
e com cancro da bexiga, o efeito do fármaco antitumoral cisplatina na 
massa muscular e, simultaneamente, foi estudado o potencial efeito 
do composto natural dimetilaminopartenolido (DMAPT) em contrariar 
o processo de catabolismo muscular. De um modo geral, a 
administração aguda de cisplatina (10 mg.kg-1 no dia zero), em 
animais saudáveis, parece não induzir a síndrome caquexia. No 
entanto, o DMAPT parece originar hipertrofia no músculo através da 
modulação do processo inflamatório e do eixo TWEAK/NF-κB (do 
inglês: tumour necrosis factor-related weak inducer of 
apoptosis/nuclear factor kappa light-chain-enhancer of activated B 
cells). Relativamente aos animais com cancro, a cisplatina aparenta 
induzir o processo de catabolismo muscular e o DMAPT parece ser 
incapaz de reverter ou melhorar este processo, apesar da sua 
capacidade de reduzir a inflamação, que por sua vez, tem uma função 
importante no desenvolvimento da caquexia. Desta forma, é 
importante descobrir a interligação específica entre as vias ativadas 
pelo cancro e as que são induzidas pelos fármacos anticancerígenos, 
com o intuito de se desenvolverem estratégias que contrariem a 
elevada morbidade e mortalidade associadas a esta síndrome. 
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Cancer cachexia (CC) is a complex metabolic syndrome that affects 
more than 50% of cancer patients, and presently, no effective 
treatment exists. A key characteristic of this condition is the 
involuntary and massive loss of skeletal muscle mass, which is related 
with a poor prognosis. The activation of catabolic pathways and the 
presence of an inflammatory state are responsible for the wasting 
process. Therefore, therapeutic approaches directed to muscle or 
inflammatory pathways may probably be effective in decreasing the 
devastating effects of cachexia. Besides the negative effects of cancer 
itself on the skeletal muscle mass, chemotherapy has also been 
associated with the development and exacerbation of this process. 
Unfortunately, the mechanisms responsible for the muscle wasting 
process induced by chemotherapy are unclear and few studies have 
been devoted to this specific problem. In this way, we investigated the 
effect on the skeletal muscle mass of the widely-used 
chemotherapeutic agent cisplatin in healthy and urothelial carcinoma-
induced animals, and simultaneously, studied the putative role of the 
natural compound dimethylaminoparthenolide (DMAPT) in counteract 
the muscle wasting process. In overall, an acute administration of 
cisplatin (10 mg.kg-1 at day zero), in healthy animals, seems to be 
incapable of induce a cachectic syndrome. Nevertheless, DMAPT 
appears to induce muscle hypertrophy through the modulation of the 
inflammatory process and the tumour necrosis factor-related weak 
inducer of apoptosis/nuclear factor kappa light-chain-enhancer of 
activated B cells (TWEAK/NF-κB) axis. However, when cancer is 
involved, cisplatin can induce muscle wasting and DMAPT looks 
unable to revert or ameliorate this process, despite its capability to 
diminish the inflammation, which in turn has an important role in the 
development of cachexia. In this way, it is important to ascertain the 
specific relation between the pathways activated by cancer itself and 
the ones induced by the anti-cancer drugs, in order to develop 
strategies to counteract the high morbidity and mortality associated 
with this condition. 
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Figure 1. Mechanism of action of cisplatin. Cisplatin enters in the cell through passive 
diffusion or by the active copper transporter 1 (Ctr1) or the organic cation transporter 2 
(Oct2). This drug can also be exported through the copper-transporting adenosine 
triphosphatase (ATPase) 1 (ATP7A) and the copper-transporting ATPase 2 (ATP7B). To 
react with deoxyribonucleic acid (DNA), the neutral cisplatin is activated by a series of 
spontaneous aquation reactions, forming [Pt(NH3)2Cl(OH2)]+ and [Pt(NH3)2(OH2)2]2+. Thus, 
the platinum binds to guanine and adenine residues, forming cisplatin-DNA adducts and 
inducing intrastrand and interstrand crosslinks. All of the cisplatin-DNA adducts distort the 
DNA structure and can be recognized by several repair pathways, including the nucleotide 
excision repair (NER) pathway, the double-strand break (DSB) repair, the translesion 
synthesis (TLS) and the proteins involved in the mismatch repair (MMR) system. If the 
degree of damage is limited, the several pathways activated culminate in DNA repair. 
Contrarily, if DNA repair fails or is overwhelmed by the extension of DNA lesions, cells 
undergo death (frequently apoptosis). In the process of apoptosis, two kinases that function 
as sensors of DNA damage are activated, named ataxia telangiectasia mutated (ATM) and 
ATM and RAD3-related protein (ATR). Figure produced using the Servier Medical Art. .... 6 
 
Figure 2. Signalling pathways modulated by cisplatin in skeletal muscle. In the 
myostatin (Mstn) pathway, this molecule binds to the activin A type IIB receptor (ActRIIB), 
resulting in its assembly with the activin A type IB receptor, ALK4 or ALK5. Consequently, 
SMAD2 and SMAD3 are activated by phosphorylation, which leads to the assembly with 
SMAD4. This heterodimer translocates to the nucleus and activate transcription of target 
genes. Thus, myostatin inhibits the myogenic programme, inducing muscle wasting. In 
addition, myostatin inhibits the insulin-like growth factor 1 (IGF-1)/phosphatidylinositol-3-
kinase (PI3K)/Akt (also known as PKB – protein kinase B)/mammalian target of rapamycin 
(mTOR) pathway, and so, the levels of muscle atrophy F-box protein (MAFbx/atrogin-1), 
muscle-specific RING-finger 1 (MuRF1) and autophagy-related genes (Atg) increase, 
resulting in a decrease in protein synthesis and an increase in protein degradation. In the 
IGF-1/PI3K/Akt/mTOR pathway, IGF-1 activates the insulin receptor substrate 1 (IRS1) and 
then Akt blocks the repression of mTOR, which in turn, regulates the skeletal muscle mass 
by mTOR complex 1 and 2 (mTORC1 and mTORC2). In the mTORC1, which requires the 
regulatory-associated protein of mTOR (RAPTOR), occurs the phosphorylation and 
activation of p70 S6 kinase (p70S6K) and inhibition of eukaryotic translation initiation factor 
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4E binding protein 1 (4E-BP1), which have as downstream targets the ribosomal protein 6 
(RPS6) and the eukaryotic translation initiator (eIF4E), respectively, leading to protein 
synthesis. Regarding mTORC2 which binds to rapamycin insensitive companion of mTOR 
(RICTOR), this molecule phosphorylates Akt, resulting in maximum Akt activation. In 
addition, Akt phosphorylates and supresses the forkhead box O (FoxO) family of 
transcription factors. However, during catabolic diseases, this signalling pathway is silenced 
and, consequently, protein synthesis decreases and protein degradation increases. The 
prototypical nuclear factor kappa light-chain-enhancer of activated B cells (NF-κB) pathway 
can be activated by tumour necrosis factor alpha (TNF-α) and interleukin 1 (IL-1). These 
molecules lead to the activation of the IkB kinase (IKK) complex, which in turn, 
phosphorylates the NF-κB-bound inhibitors of NF-κB (IκBαs), which are target for 
polyubiquitination and degradation. The released NF-κB free dimers (p50/p65) translocate 
to the nucleus and induce the expression of MAFbx/atrogin-1 and MuRF1. Regarding 
interleukin 6 (IL-6), this cytokine can signalling through the Janus kinase/signal transducers 
and activators of transcription (JAK/STAT) pathway, resulting in the suppression of protein 
synthesis. Legend: Act A: activin A | ALP: autophagy-lysosome pathway | Bnip3: B cell 
lymphoma 2/adenovirus E1B 19-kDa protein-interacting protein 3 | gp130: glycoprotein 130 
| IGF-1R: IGF-1 receptor | IL-1R: IL-1 receptor | IL-6R: IL-6 receptor | LC3: microtubule-
associated protein 1 light chain 3 | TNF-αR: TNF-α receptor | UPP: ubiquitin-proteasome 
pathway. Figure produced using the Servier Medical Art. ................................................ 12 
 
Figure 3. Possible therapeutic approaches for cachexia and muscle wasting. Ghrelin 
administration increases appetite and muscle mass. Clarithromycin decreases serum levels 
of interleukin 6 (IL-6), improving the cachectic status. Regarding thalidomide, this agent 
attenuates weight loss, possible (?) through downregulation of pro-inflammatory cytokines, 
such as tumour necrosis factor alpha (TNF-α) and /or through the inhibition of prototypical 
nuclear factor kappa light-chain-enhancer of activated B cells (NF-κB). In addition, the use 
of celecoxib demonstrated a significant decrease in serum levels of TNF-α and increase in 
lean body mass. The use of an activin A type IIB receptor (ActRIIB) decoy receptor 
(sActRIIB), results in the inhibition of the myostatin pathway, and also, prevents the 
activation of muscle atrophy F-box protein (MAFbx/atrogin-1) and muscle-specific RING-
finger 1 (MuRF1). In addition, activate the insulin-like growth factor 1 (IGF-
1)/phosphatidylinositol-3-kinase (PI3K)/Akt (also known as PKB – protein kinase 
B)/mammalian target of rapamycin (mTOR) pathway, thus preserving muscle mass. 
Resveratrol and the nemo-binding domain (NBD) peptide are inhibitors of the NF-κB 
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pathway, and so, decrease the expression of MuRF1 and MAFbx/atrogin-1. Finally, the 
eicosapentaenoic acid (EPA), decreases pro-inflammatory cytokines release and inhibit 
NF-κB. .............................................................................................................................20 
 
Figure 4. Schematic figure representing the experimental procedures performed in the (A) 
study 1 and (B) study 2. In study 1 the animals were divided in three groups – control (n=5), 
cisplatin (n=5) and cisplatin + dimethylaminoparthenolide (DMAPT) (n=5) –, whereas the 
study 2 was constituted by five experimental groups – control (n=15), N-butyl-N-(4-
hydroxybutyl)-nitrosamine (BBN) (n=19), BBN + cisplatin (n=18), BBN + DMAPT (n=17), 
BBN + cisplatin + DMAPT (n=19). In both studies serum analysis was done through slot 
blot assays, while western blot analysis, zymography and spectrophotometric assay were 
only conducted in study 1 in order to analyse the gastrocnemius muscle. The proteins 
analysed are below the corresponding assays. Legend: ATP: adenosine triphosphate | 
CRP: C reactive protein | GAPDH: glyceraldehyde 3-phosphate dehydrogenase | IκBα: 
inhibitors of NF-κB | IL-6: interleukin-6 | MAFbx/atrogin-1: muscle atrophy F-box protein | 
MMP: metalloproteinase | MuRF1: muscle-specific RING-finger 1 | NF-κB: prototypical 
nuclear factor kappa light-chain-enhancer of activated B cells | TWEAK: tumour necrosis 
factor-related weak inducer of apoptosis. Figure produced using the Servier Medical Art..32 
 
Figure 5. Effect of cisplatin or cisplatin plus DMAPT administration on (A) CRP, (B) TWEAK, 
(C) IL-6 and (D) ghrelin serum levels. Representative immunoblots are presented above the 
corresponding graphs. Values are expressed as mean ± standard deviation. (* p<0.05) .40 
 
Figure 6. Effect of cisplatin or cisplatin plus DMAPT administration on the muscle 
expressions of (A) ATP synthase and (B) GAPDH. Representative immunoblots are 
presented in (C). It is also presented the (D) ATP synthase/GAPDH ratio. In (E) the citrate 
synthase activity can be observed. The values are expressed as mean ± standard deviation.
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Figure 7. Effect of cisplatin or cisplatin plus DMAPT administration on the muscle 
expressions of (A) TWEAK, (B) NF-κB p105/50, (C) NF-κB p65 and (D) IκBα. Representative 
immunoblots are presented in (E). The values are expressed as mean ± standard deviation. 
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expression of (A) MuRF1 and (B) MAFbx/atrogin-1. Representative immunoblots are 
presented in (C). (D) Representative  zymography gel, evidencing one band with proteolytic 
activity. In (E) is presented the semi-quantitative analysis of the proteolytic activity for each 
group. The values are expressed as mean ± stan-dard deviation. (* p<0.05) .................. 43 
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 Cancer is the second leading cause of death worldwide and its occurrence is 
expected to increase because of the growth and aging of the population. [1,2] In 2012, about 
14.1 million new cancer cases and 8.2 million deaths were estimated to have occurred. [2] 
In 2015, the number of deaths increased to over 8.7 million. [1] This complex disease is 
characterized by an uncontrolled growth of abnormal cells that have become capable to 
invade adjacent tissues and colonize other organs. [3] A common and debilitating 
complication of cancer is a metabolic syndrome termed cachexia. [4] The etiology of this 
syndrome is not well established and, therefore, no standardized assessment procedure 
exists nor therapies to prevent or treat cancer cachexia (CC). [5–7] This condition is 
characterized by the progressive wasting of fat tissue and skeletal muscle, despite 
adequate nutrition, thus negatively affecting the prognosis and quality of life of cancer 
patients. [4,8] Indeed, one of the main features of cachexia is the involuntary loss of skeletal 
muscle mass, known as muscle wasting, which contributes to the functional muscle 
impairment observed in cancer patients and to the difficulties related with the clinical 
delivery of chemotherapy. [9,10] Cancer treatments, such as chemotherapy, may also 
contribute to the development of cachexia. [11] In fact, chemotherapy negatively alters 
patient’s nutritional state, and also, decreases the body weight. [12,13] Some cytotoxic 
drugs may generate their own cachexia-like side-effects, through the increased activity of 
various mediators involved in the molecular pathways underlying muscle wasting. [12–14] 
Nevertheless, few studies have been dedicated to the comprehension of the association 
between cancer treatments and the development of cachexia, which is responsible for more 
than 20% of all cancer-related deaths. [4,11,12,15] Therefore, the preservation of body 
weight through the prevention and treatment of skeletal muscle wasting may increase 
survival chances of cancer patients and improve their quality of life. [16] 
1. THE IMPACT OF CHEMOTHERAPY IN CANCER TREATMENT 
 In the middle of the 20th century, chemotherapy emerged. [17] One of the first events 
that lead to the development and use of chemotherapeutic agents was performed by Sidney 
Farber, the father of the modern era of chemotherapy, in 1948. [18,19] He reported that folic 
acid antagonists could induce temporary remission in child patients with acute leukemia. 
[20] Since then, chemotherapy has become one of the principal treatment approaches in 
cancer treatment, influencing the treatment and survival of these patients. [17,21] In fact, 
chemotherapy is effective in the treatment of several malignancies, including 
choriocarcinoma, Hodgkin’s and non-Hodgkin’s lymphoma and germ cell, small cell lung, 
ovarian and testicular cancer. [17,22] This therapeutic approach usually involves the 
4 
 
administration of anticancer drugs in a standardized treatment regimen, which is specific 
for the type of cancer, with the aim of inducing tumour cell death. [13,23]  
 Chemotherapeutic drugs can be classified into alkylating agents (e.g. cisplatin and 
busulfan), antitumour antibiotics (e.g. mitoxantrone and bleomycin), antimetabolites (e.g. 
aminopterin and cytarabine), mitotic inhibitors (e.g. vinblastine and paclitaxel), 
topoisomerase inhibitors (e.g. etoposide and topotecan), corticosteroids, hormones and 
antagonists (e.g. tamoxifen and bicalutamide) and biologically targeted agents including 
tyrosine kinase inhibitors, antibiotics and other pathway inhibitors. [21] The agents that are 
frequently used induce cell death through apoptosis, mitotic catastrophe and premature 
senescence. The cytotoxic agents damage the deoxyribonucleic acid (DNA) or other critical 
molecules, which activate cellular effector systems, including the apoptotic machinery in 
cancer cells. However, cytotoxic chemotherapy is associated with many deleterious side-
effects, such as myelosuppression and gastrointestinal and pulmonary toxicity. [15]  
 Conventional chemotherapy is frequently related with the development of drug 
resistance and systemic toxicity, which limits its therapeutic effectiveness. [24] This 
resistance to chemotherapeutics can be divided into intrinsic or acquired. [25] In intrinsic 
resistance, resistance-mediating factors pre-exist in the bulk of the tumour cells, making the 
treatment ineffective. Contrarily, in acquired resistance, the tumour is sensitive in the 
beginning of the treatment, but resistance is developed in the course of the therapy. This 
acquired resistance can be caused by mutations that appear during the treatment and by 
numerous other adaptive responses, including activation of alternative compensatory 
pathways and increased expression of the therapeutic target. Thus, alternative approaches 
are being development in order to decrease or abolish these therapy-related complications. 
[24] The improvements made so far include the use of chemotherapy in combination with 
other treatment modalities, such as immunotherapy, angiogenesis inhibition therapy, 
differentiation therapy and radiotherapy. These multiple treatment protocols have the aim 
to eliminate the complications related with cancer cell resistance to a specific drug or class 
of drugs and to decrease toxicity linked to high-dose chemotherapy. The drugs presently 
used for cancer treatment are not tumour-specific, and therefore, are frequently related with 
severe side-effects, such as immunosuppression and cardiotoxicity. Additionally, it is 
possible that chemotherapy may directly promote cachexia; however, the mechanisms 
involved are less well described. [11,15] Among the chemotherapeutic drugs related to 
cachexia, attention has been given to cisplatin; nevertheless, few studies have been 
addressed to the comprehension of the mechanisms responsible for cisplatin-induced 
muscle wasting. [13,15] Thus, this will be the agent studied in the present work. 
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 1.1. The chemotherapeutic effect of cisplatin 
 Cisplatin (cis-diammine-dichloro-platinumII or cis-[PtCl2(NH3)2] or CDDP), an organic 
platinum-based chemotherapeutic agent, is one of the most potent and effective broad-
spectrum anticancer drugs used. [13,23,26,27] It contains a platinum core with two amine 
nonleaving groups and two chloride leaving groups. [19] This anticancer agent was 
synthetized for the first time in 1845 and its structure deduced in 1893 by Alfred Werner. 
However, it was only in the 1960s that cisplatin was discovered as an anticancer drug and 
in 1978 was approved by the Food and Drug Administration (FDA) for the treatment of 
testicular and bladder cancer. [23,28] Nowadays, cisplatin integrates the standard of care 
for the treatment of several human tumours including head and neck, ovary and bladder 
cancer. [29] As a matter of fact, treatment with cisplatin has good efficacy in the therapy of 
these types of cancer, and also, of cervical cancer and can cure over 90% of all testicular 
cancer cases. [19] Consequently, these types of cancer received better prognosis, 
becoming less life threatening. [23] Cisplatin, which is administered intravenously, 
frequently results in an initial therapeutic success related to partial responses or disease 
stabilization. [28] Nevertheless, the use, efficacy and therapeutic profile of this anticancer 
agent are limited due to side-effects in normal tissues. [23,30] Such reversible and 
irreversible side-effects include nephrotoxicity, neurotoxicity, ototoxicity, hypomagnesemia, 
gastrointestinal toxicity, myelosuppression, hair loss, nausea and emesis. [15,27,30,31] 
The substantial neurotoxicity expresses as peripheral neuropathy, cachexia and anorexia. 
[32] In fact, it is usually observed in cancer patients treated with cisplatin a significant body 
weight loss, mainly due to muscle atrophy. [33]  These complications frequently intensify 
the pain, anorexia and cachexia induced by the tumour itself. [32] Cisplatin-related toxicities 
are dose-dependent, so overdose may cause significant morbidity and/or mortality. [23] The 
incidence of cisplatin overdose is not known and, until now, general guidelines to manage 
a cisplatin overdose or a specific antidote do not exist. [23]   
 Cisplatin is a DNA-damaging agent, being generally accepted that genomic DNA is 
the primary target of this drug. [30] Since the discovery of the clinical benefits of cisplatin, 
studies have been made in order to understand how this chemotherapeutic agent works. 
[26,34–37] There are some gaps in the knowledge of the mechanisms underlying cisplatin-
induced DNA damage. [38] In mammals, the uptake of cisplatin occurs through passive 
diffusion or involving the active copper transporter 1 (Ctr1) or the organic cation transporter 
2 (Oct2) (Figure 1). [39,40] This drug can also be exported through copper-transporting 
adenosine triphosphatase (ATPase) 1 (ATP7A) and copper- transporting ATPase 2 
(ATP7B), and can also be inactivated by reduced glutathione (GSH) or metallothionein. [40] 
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It is important to notice that the intracellular concentration of cisplatin determines the extent 
of the DNA lesions and, consequently, the efficacy of apoptosis machinery activation. To 
react with DNA, the neutral cisplatin needs to be activated through a series of spontaneous 
aquation reactions involving the successive replacement of cis-chloro ligands of the drug 
with water molecules. [26] Therefore, once inside the cell, cisplatin undergoes aquation to 
form [Pt(NH3)2Cl(OH2)]+ and [Pt(NH3)2(OH2)2]2+, a process that is facilitated by the low 
cellular concentrations of chloride ions (approximately 2-10 mM when compared with 
approximately 100 mM in the extracellular milieu). [28,31] Moreover, the aquated form is a 
positively charged molecule more reactive towards the cellular targets, in particular with 
endogenous nucleophiles, including GSH, methionine, metallothioneins, proteins (via their 
sulfhydryl groups on cysteines) and nitrogen donor atoms on nucleic acids. [28,30,38,39]  
Figure 1. Mechanism of action of cisplatin. Cisplatin enters in the cell through passive diffusion or by the 
active copper transporter 1 (Ctr1) or the organic cation transporter 2 (Oct2). This drug can also be exported 
through the copper-transporting adenosine triphosphatase (ATPase) 1 (ATP7A) and the copper-transporting 
ATPase 2 (ATP7B). To react with deoxyribonucleic acid (DNA), the neutral cisplatin is activated by a series of 
spontaneous aquation reactions, forming [Pt(NH3)2Cl(OH2)]+ and [Pt(NH3)2(OH2)2]2+. Thus, the platinum binds 
to guanine and adenine residues, forming cisplatin-DNA adducts and inducing intrastrand and interstrand 
crosslinks. All of the cisplatin-DNA adducts distort the DNA structure and can be recognized by several repair 
pathways, including the nucleotide excision repair (NER) pathway, the double-strand break (DSB) repair, the 
translesion synthesis (TLS) and the proteins involved in the mismatch repair (MMR) system. If the degree of 
damage is limited, the several pathways activated culminate in DNA repair. Contrarily, if DNA repair fails or is 
overwhelmed by the extension of DNA lesions, cells undergo death (frequently apoptosis). In the process of 
apoptosis, two kinases that function as sensors of DNA damage are activated, named ataxia telangiectasia 
mutat 
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 Due to the aquation of the chloride groups, the platinum binds to guanine and 
adenine (to a smaller extent) residues, forming cisplatin-DNA adducts and inducing 
intrastrand and interstrand crosslinks. [19,30,31] More specifically, the platinum atom of 
cisplatin forms covalent bonds with the N7 reactive centre on purine bases, resulting from 
this interaction between cisplatin and DNA: 1,2-intrastrand crosslinks involving adjacent 
guanine bases (GpG, 47-50%), 1,2-intrastrand crosslinks involving adjacent adenine and 
guanine bases (ApG, 23-28%), 1,3-intrastrand crosslinks involving nonadjacent guanines 
(cis-GNG), interstrand adducts (8-10%) and monofunctional binding to guanine (2-3%). 
[31,38,39] It has been indicated that the most important cisplatin-induced DNA lesions are 
the 1,2-intrastrand ApG and GpG, suggesting that these intrastrand adducts are responsible 
for most, if not all, cisplatin cytotoxicity. [26] All of the cisplatin-DNA adducts bend and 
unwind the DNA helix (i.e. distorting its structure), thus interfering with DNA replication 
and/or transcription, which result in DNA damage followed by cell-cycle arrest and cell 
death. [30,31,41] The Pt-DNA biofunctional adducts influence the cell life through two 
principal mechanisms – interaction with cellular proteins and inhibition of ribonucleic acid 
(RNA) transcription. [38] Among the various theories proposed to explain the mechanisms 
responsible for transcription inhibition, one of them is based on the blocking of the 
polymerase. This is due to the Pt-DNA crosslink, a barrier to translocation, whereby the 
bases in the platinated dinucleotide cannot rotate correctly in order to enter into the enzyme 
active site. [38] 
 The distortions in DNA can be recognized by numerous repair pathways. [28] It is 
thought that the nucleotide excision repair (NER) represents the principal mechanism for 
the removal of cisplatin adducts, since it is responsible for the repair of the intrastrand 
crosslinks. [28,40] With regard to the interstrand crosslinks, a complex mechanism for their 
repair is required, including the components of NER, double-strand break (DSB) repair and 
translesion synthesis (TLS). [40] Additionally, proteins involved in the mismatch repair 
(MMR) system also contribute to the recognition and resolution of cisplatin lesions. [28] If 
the degree of damage is limited, the cisplatin adducts activate several pathways that 
culminate in DNA repair. [26,28,40] One of these pathways involves the activation of cell 
cycle checkpoints, which temporally results in S-phase arrest, followed by inhibition of the 
cyclin A or B kinase, which in turn induces a durable G2/M arrest. [28] This process has 
cytoprotective effects, being re-established the DNA integrity through repair mechanisms 
and prevention of potentially abortive or abnormal mitoses. Contrarily, if DNA repair fails or 
 mutated (ATM) and ATM and RAD3-related protein (ATR). Figure produced using the Servier Medical Art. 
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is overwhelmed by the extension of DNA lesions, cells undergo death (frequently 
apoptosis). [26,28,40] 
 When the cisplatin-induced DNA lesions lead to apoptosis, two kinases that function 
as sensors of DNA damage are activated, named ataxia telangiectasia mutated (ATM) and 
ATM and RAD3-related protein (ATR). [26,28] ATM is principally activated by cisplatin-
induced DSBs, owing to continuous replication blockage, which causes collapse of 
replication forks, whereas ATR is activated due to stalled DNA replication forks. [40] 
Cisplatin preferentially activates ATR kinase, which phosphorylates tumour suppression 
protein p53 at serine-15 in order to initiate the activation of p53. [26] In addition, ATR 
activates the checkpoint kinase 1 (CHK1), which is the principal substrate and downstream 
effector of ATR. [26,28] CHK1 phosphorylates p53 on serine 20, stabilizing it. [28] Activated 
p53 signals to lethal functions through nuclear and cytoplasmic mechanisms that ultimately 
result in mitochondrial outer membrane permeabilization or increased signalling via death 
receptors followed by cell death. This process of apoptosis is initiated with the translocation 
of the cisplatin-induced Bax from the cytosol to the mitochondria. [26] In this organelle, a 
cascade of events occurs, including the release of apoptogenic factors (such as cytochrome 
c), which triggers the caspase-9/caspase-3 pathway, resulting in apoptosis. In addition, ATR 
has been linked to the activation of numerous specific branches of the mitogen-activated 
protein kinase (MAPK) cascade, including those mediated by extracellular signal-regulated 
kinases (ERK), c-JUN N-terminal kinases (JNKs or stress-activated protein kinases - SAPK) 
and p38 kinases, which phosphorylates p53 in various positions. [26,28] These MAPK 
members are involved in the regulation of cell proliferation, cell differentiation, cell survival 
and apoptosis. [26] The contribution of these pathways to the cytotoxic effects of cisplatin 
continues to be clarified. [28] Interestingly, ATM seems to be involved in cisplatin-induced 
cell cycle arrest but not cell death. Nonetheless, CHK2, which is the main downstream target 
of ATM, has been implicated in cisplatin-induced lethal signals in an ATM-independent 
manner. [28] 
Cisplatin-based chemotherapy is related with high morbidity due to complications 
like malnutrition, cachexia, chemotherapy resistance and psychosocial distress, which 
adversely affects both quality of life and survival of cancer patients. [21,42,43] Cisplatin is 
regularly associated with marked side-effects, such as diarrhea, nausea, anorexia and 
fatigue. Cisplatin is a highly emetogenic chemotherapeutic agent, thus resulting in a 
decrease in appetite and, consequently, weight loss. [32] Regarding cachexia, cancer 
treatments may contribute to the development of this syndrome; however, its causative role 
is not completely understood, with few studies devoted to the comprehension of the 
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association between cancer treatment and the development of cachexia. [11,15] As a 
matter of fact, cancer patients with muscle wasting are more predisposed to develop severe 
drug-associated toxicity and present a poorer prognosis. [11] In opposition, patients with 
preserved muscle mass are normally more resistant to chemotherapy side-effects and may 
even tolerate higher doses of chemotherapy. [29] In fact, muscle fatigue is one of the most 
common side-effects of cisplatin during and after treatment. [13] Therefore, to increase the 
chances of a successful treatment and improve quality of life, the development of 
therapeutic strategies to counteract or attenuate these cancer-related complications is of 
enormous importance in the clinical practice. [13]  
2. CANCER CACHEXIA: PATHOPHYSIOLOGIC MECHANISMS 
 A devastating complication of cancer is cachexia, a complex metabolic syndrome 
that means “bad condition”, from the Greek kakos (i.e. bad) and hexis (i.e. condition or 
appearance). [4,44] The common features among the several definitions of cachexia are 
weight loss, mostly because of the loss of skeletal muscle and body fat, and inflammation. 
[45] This life-threatening condition is related to numerous diseases, being very important in 
the setting of cancer since it affects more than 50% of all cancer patients and has a 
prevalence of about 86% in patients with advanced disease. [4,33,46] Cachexia is more 
prevalent in patients with solid tumours such as lung, pancreatic, colorectal or gastric 
cancer. [5,10] The development of cachexia is a strong predictor of morbidity and mortality, 
being responsible for 25-30% of all cancer-related deaths. Both weight loss and rate of 
weight loss correlate positively with mortality. [4] This wasting condition also decreases the 
efficacy and increases the toxicity of chemotherapy. [5,47] Presently, the moment when this 
condition appears in the clinical history of cancer patients is, generally, unpredictable. [48] 
 Pathophysiologically, CC is characterized by a negative protein balance (i.e. 
increased proteolysis and decreased protein synthesis) and energy imbalance (i.e. 
increased energy expenditure rate). [10,44] In fact, these profound alterations may be 
irreversible at the moment of evident weight loss. [48] Clinically, this syndrome is 
characterized by a weight loss of at least 5% in 6 months, in the presence of underlying 
illness and can be categorized as mild, moderate or severe corresponding to a weight loss 
of 5%, 10% or 15% of total body weight, respectively. [4] CC is associated with anorexia, 
early satiety, asthenia, fatigue, muscle weakness, skeletal muscle atrophy, low lean body 
mass, abnormal biochemistry (including increased inflammation, anaemia and low serum 
albumin) and impaired metabolic functions, like insulin resistance. [4,5,33,45,49]  
Several mechanisms have been suggested to participate in the pathogenesis of CC, 
and therefore, it is considered a multifactorial and multi-organ syndrome, involving 
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metabolic pathways harboured in several organs (such as skeletal muscle and adipose 
tissue – both brown and white adipose tissues –, as well as brain, liver, gut and heart). 
[8,45] Although the etiology of this condition has not been established, several cellular and 
molecular mechanisms have been suggested, for instance, systemic inflammation, 
oxidative stress, metabolic disturbances and nutritional abnormalities. [7,8] By the fact that 
not all types of cancer promote CC, it is suggested that specific cancer cell-generated 
humoral factors are essential to the development of this wasting syndrome. [5] Despite the 
clinical studies performed so far and focused on the mechanisms of cachexia and targets 
for therapeutic interventions, no standardized assessment or treatments to prevent or treat 
cancer cachexia are currently available. [5,6,49] Thus, efforts continue to be made to better 
comprehend the molecular basis of CC envisioning the development of strategies to 
counteract the high morbidity and mortality associated with this syndrome. [50]  
 2.1. Cancer-induced muscle wasting 
 Skeletal muscle contributes to more than 40% of body weight – being the principal 
protein reservoir in the body – and seems to be the main wasted tissue in CC. [45,51] In 
fact, cachectic patients mainly demonstrate lean mass depletion particularly in the 
appendicular body compartment. [52] Since this area is predominantly composed of muscle 
mass, it seems that a specific loss of skeletal muscle occurs. Thereby, a key characteristic 
of cachexia is the involuntary loss of skeletal muscle mass, known as muscle wasting, which 
leads, along with other causes, to the functional impairment of skeletal muscle observed in 
CC and to the complications associated with the clinical delivery of chemotherapy. [9,10] 
Contrary to what happens in muscle atrophy caused by starvation or physical inactivity, 
muscle wasting in cachectic patients cannot be inverted by nutritional supplementation. [6] 
The loss of skeletal muscle mass seems to be closely related with the tumour size, stage 
and the type of anticancer drug used. [33] Several molecular mechanisms seem to be 
responsible for the cancer-induced loss of muscle mass, being modulated by the interaction 
between tumour and host factors. [5,33]  Nevertheless, CC is not caused only by the cancer 
per se, being that the antineoplastic treatments, such as chemotherapy, may also contribute 
to the development and exacerbation of this syndrome. [53]  
Cancer therapeutics are related with the development of systemic inflammation, 
intensification of the already-reduced energy and swallowing problems and anorexia due to 
nausea, which results in a negative effect on the nutritional intake of the patient. [12,53,54] 
Chemotherapy can induce anorexia, nausea, vomiting, mucositis, taste change or lethargy, 
thus interfering with the maintenance of the patient’s nutritional state. [12] These symptoms 
are associated with the nature and course of the chemotherapeutic drugs used and some 
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cytotoxic drugs may generate their own cachexia-like side-effects. In fact, administration of 
the chemotherapeutic agents cisplatin or folfiri decreases body weight, including the skeletal 
muscle mass. [11,13] In addition, several studies reveal that cisplatin administration 
increases the activity of various mediators involved in the molecular pathways related to the 
muscle wasting process. [13,14] However, the association between CC and the effects of 
chemotherapy remains to be fully understood, being that different chemotherapy agents 
induce cachexia through different mechanisms, and so, future research is needed in order 
to understand their transduction pathways. [12,54]  
Among the molecular pathways involved in the regulation of muscle mass are the 
ubiquitin-proteasome pathway (UPP), the autophagy-lysosome pathway (ALP), the insulin-
like growth factor (IGF)-1/phosphatidylinositol-3-kinase (PI3K)/Akt (also known as PKB – 
protein kinase B)/mammalian target of rapamycin (mTOR) pathway, the myostatin pathway 
and the MAPK pathway (Figure 2). [5,10,13,29] The UPP seems to be responsible for the 
degradation of myofibrillar and specific regulatory proteins involved in muscle protein 
expression; the ALP targets the degradation of mitochondria and other cellular components; 
the overexpression of IGF-1/PI3K/Akt/mTOR pathway leads to muscle hypertrophy; and the 
activation of the myostatin pathway leads to atrophy. [5,13] Moreover, CC-related muscle 
wasting is accompanied by systemic inflammation. [5,13] 
Systemic inflammation is an important host-related alteration that promotes muscle 
wasting, through the overrepresentation of pro-inflammatory cytokines and down-
expression of anti-inflammatory cytokines. [52,55,56] In cancer, inflammation is a double-
edged sword because, apart from the natural function of the immune system in regulating 
tumour growth, cancer cells induce the immune system to produce particular cytokines that 
stimulate tumour growth, progression and survival. [46] In fact, pro-inflammatory cytokines 
secreted both by immune cells or tumours can directly stimulate pathways that promote 
skeletal muscle protein turnover. [45] In addition, pro-inflammatory cytokines increase the 
metabolic rate due to the activation of thermogenesis, inhibit skeletal myocyte differentiation 
and decrease food intake. [48] Several pro-inflammatory mediators such as interleukin (IL) 
1 beta (IL-1β), IL-6, interferon gamma (IFN-γ), transforming growth factor beta (TGF-β) and 
leukemia inhibitor factor (LIF) have been associated with the pathogenesis of muscle 
wasting, but emphasis has been given to the pro-inflammatory cytokine tumour necrosis 
factor alpha (TNF-α). [9] These molecules, principally TNF-α, are powerful activators of the 
prototypical nuclear factor kappa light-chain-enhancer of activated B cells (NF-κB) 
transcription factor (p65/p50). [55] In contrast with the upregulation of the pro-inflammatory 
cytokines, a decrease in the expression of anti-inflammatory cytokines simultaneously 
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Figure 2. Signalling pathways modulated by cisplatin in skeletal muscle. In the myostatin (Mstn) pathway, 
this molecule binds to the activin A type IIB receptor (ActRIIB), resulting in its assembly with activin A type IB 
rec  
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occurs, including IL-4, IL-10 and IL-12. [46] Furthermore, cisplatin treatment induces the 
expression of the pro-inflammatory cytokines TNF-α and IL-6 and diminishes the expression 
of the anti-inflammatory cytokine IL-10. [57] Despite the recognized importance of 
inflammation in the pathogenesis of CC, anti-inflammatory drugs had no success in the 
reversion of CC. [58] So, other biological processes might also be equally important in the 
pathogenesis of CC. [58] 
 2.1.1. Ubiquitin-proteasome pathway  
The UPP is the principal pathway involved in the intracellular protein degradation of 
skeletal muscle fibres. [33] This pathway is composed by ubiquitin-activating enzymes (E1), 
ubiquitin-carrier or conjugating proteins (E2s) and ubiquitin-protein ligases (E3s), and 
involves two successive steps. [33,51] Firstly, occurs the polyubiquitination, that is, the 
covalent attachment of ubiquitin chains to the targeted protein substrate. This process 
receptor, ALK4 or ALK5. Consequently, SMAD2 and SMAD3 are activated by phosphorylation, which leads to 
the assembly with SMAD4. This heterodimer translocates to the nucleus and activate transcription of target 
genes. Thus, myostatin inhibits the myogenic programme, inducing muscle wasting. In addition, myostatin 
inhibits the insulin-like growth factor 1 (IGF-1)/phosphatidylinositol-3-kinase (PI3K)/Akt (also known as PKB – 
protein kinase B)/mammalian target of rapamycin (mTOR) pathway, and so, the levels of muscle atrophy F-box 
protein (MAFbx/atrogin-1), muscle-specific RING-finger 1 (MuRF1) and autophagy-related genes (Atg) increase, 
resulting in a decrease in protein synthesis and an increase in protein degradation. In the IGF-1/PI3K/Akt/mTOR 
pathway, IGF-1 activates the insulin receptor substrate 1 (IRS1) and then Akt blocks the repression of mTOR, 
which in turn, regulates the skeletal muscle mass by mTOR complex 1 and 2 (mTORC1 and mTORC2). In the 
mTORC1, which requires the regulatory-associated protein of mTOR (RAPTOR), occurs the phosphorylation 
and activation of p70 S6 kinase (p70S6K) and inhibition of eukaryotic translation initiation factor 4E binding 
protein 1 (4E-BP1), which have as downstream targets the ribosomal protein 6 (RPS6) and the eukaryotic 
translation initiator (eIF4E), respectively, leading to protein synthesis. Regarding mTORC2, which binds to 
rapamycin insensitive companion of mTOR (RICTOR), this molecule phosphorylates Akt, resulting in maximum 
Akt activation. In addition, Akt phosphorylates and supresses the forkhead box O (FoxO) family of transcription 
factors. However, during catabolic diseases, this signalling pathway is silenced and, consequently, protein 
synthesis decreases and protein degradation increases. The prototypical nuclear factor kappa light-chain-
enhancer of activated B cells (NF-κB) pathway can be activated by tumour necrosis factor alpha (TNF-α) and 
interleukin 1 (IL-1). These molecules lead to the activation of the IkB kinase (IKK) complex, which in turn, 
phosphorylates the NF-κB-bound inhibitors of NF-κB (IκBαs), which are target for polyubiquitination and 
degradation. The released NF-κB free dimers (p50/p65) translocate to the nucleus and induce the expression of 
MAFbx/atrogin-1 and MuRF1. Regarding interleukin 6 (IL-6), this cytokine can signalling through the Janus 
kinase/signal transducers and activators of transcription (JAK/STAT) pathway, resulting in the suppression of 
protein synthesis. Legend: Act A: activin A | ALP: autophagy-lysosome pathway | Bnip3: B cell lymphoma 
2/adenovirus E1B 19-kDa protein-interacting protein 3 | gp130: glycoprotein 130 | IGF-1R: IGF-1 receptor | IL-
1R: IL-1 receptor | IL-6R: IL-6 receptor | LC3: microtubule-associated protein 1 light chain 3 | TNF-αR: TNF-α 
receptor | UPP: ubiquitin-proteasome pathway. Figure produced using the Servier Medical Art. 
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implies the sequential action of the E1, E2 and E3. [51] Subsequently, this complex can be 
recognized by the 26S proteasome, which digests the substrate into peptides. [33,51] Two 
muscle-specific E3 ligases – muscle-specific RING-finger 1 (MuRF1) and muscle atrophy 
F-box protein (MAFbx - also known as atrogin-1) – appear to be overexpressed in various 
catabolic conditions. The transcription factor forkhead box O (FoxO) is responsible for the 
increased transcription of MuRF-1 and MAFbx/atrogin-1. [59] These molecules are 
responsible for the ubiquitination and degradation of muscle proteins by the proteasome. 
[33] In fact, the deletion of MAFbx/atrogin-1 and MuRF1 protects the skeletal muscle in 
cases of experimental atrophy. [60] Contrarily, administration of cisplatin increases the 
expression levels of MAFbx/atrogin-1 and MuRF1. [13] The UPP is up-regulated by several 
cytokines, hormones (such as glucocorticoids) and myostatin, and inhibited by insulin or 
IGF-1. [60] It is thought that the elevated activity of this pathway in cachexia is induced by 
the activation of FoxO and NF-κB transcription factors, inducing the MuRF-1 and 
MAFbx/atrogin-1, and so, the proteasome activity. [61] 
 2.1.2. Autophagy-lysosome pathway 
 Autophagy may occur through macroautophagy, microautophagy, selective 
macroautophagy and microautophagy. [62] Macroautophagy (hereafter referred as 
autophagy) is used by the skeletal muscle to transport cytoplasm, organelles and proteins 
to the lysosome for degradation. [63] In this process occurs the sequestration of cytoplasmic 
components (e.g. long-lived or malfunctioning proteins and obsolete or damaged 
organelles) into double-membrane vesicles (i.e. autophagosomes), which subsequently 
fuse with lysosomes and their contents are digested by hydrolases and recycled. [62,64] 
The principal steps of this process – autophagy initiation, nucleation and lysosome 
fusion/degradation – are controlled by a family of evolutionary and conserved autophagy-
related genes (Atg) proteins. [63] Autophagy occurs at physiological levels in all eukaryotic 
cells in order to remove misfolded proteins and damaged organelles and to prevent protein 
aggregates accumulation. However, the excessive and abnormal activation of this process 
during catabolic states exacerbates the process of muscle wasting, with the consequent 
impairment of myofiber homeostasis, leading to an excessive removal of cellular 
components needed for normal activities. [65,66] Indeed, abnormal autophagic protein 
degradation has been associated with several human diseases, including cancer. [67] 
Accordingly, components of the wasting process seem to mediate autophagy, including Akt, 
mTOR, pro-inflammatory cytokines and NF-κB activation. [62,63] In addition, FoxO3 has 
been implicated in the control of the autophagic degradation pathway in skeletal muscle, 
through the regulation of the expression of key Atg, including the microtubule-associated 
15 
 
protein 1 light chain 3 (LC3) and B cell lymphoma 2/adenovirus E1B 19-kDa protein-
interacting protein 3 (Bnip3). [63]  
The FoxO family is constituted by three members, being of notice FoxO1 and FoxO3 
that are probably activated in all types of atrophy and can induce the expression of UPP 
and Atg, including LC3 and Bnip3, which are important markers of autophagosome 
formation. [12,16,68] Actually, activation of FoxO3 alone is sufficient to activate proteolysis 
through UPP and autophagy and, consequently, to cause significant atrophy. [16] Both 
FoxO1 and FoxO3 activity is strongly controlled by various post-translational modifications. 
On the one hand, FoxO3 is stimulated by phosphorylation by mammalian sterile 20-like 
protein kinase 1 (MST1) or 5´-adenosina monophosphate-activated protein kinase (AMPK). 
On the other hand, FoxO3 transcriptional activity is inhibited through phosphorylation by 
Akt, deacetylation by sirtuin 1 (SIRT1), ubiquitination or binding to JUNB or peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). [16]  
 2.1.3. IGF-1/PI3K/Akt/mTOR pathway 
 IGF-1 signalling is possibly the best-characterized pathway related to muscle 
hypertrophy. [45] In most cells, this pathway controls cell division. [16] However, in the non-
dividing muscle fibres, the IGF-1/PI3K/Akt/mTOR pathway promotes protein synthesis and 
inhibits protein degradation. Thus, IGF-1 activates insulin receptor substrate 1 (IRS1)-PI3K-
Akt signalling, and then Akt blocks the repression of mTOR, which in turn, regulates skeletal 
muscle mass by two different complexes, termed mTOR complex 1 and 2 (mTORC1 and 
mTORC2). [45,69] In the mTORC1, which requires an adaptor protein named regulatory-
associated protein of mTOR (RAPTOR), occurs the phosphorylation and activation of p70 
S6 kinase (p70S6K) and inhibition of eukaryotic translation initiation factor 4E binding 
protein 1 (4E-BP1), which have as downstream targets the ribosomal protein 6 (RPS6) and 
the eukaryotic translation initiator (eIF4E), respectively, leading to protein synthesis. [69–
71] Regarding mTORC2, which binds to rapamycin-insensitive companion of mTOR 
(RICTOR), this complex phosphorylates Akt at serine 473 through a mechanism of positive 
feedback, thus allowing maximum Akt activation. [71] However, mTORC2 inhibition induces 
autophagy mainly through FoxO3. [69,72] Furthermore, Akt phosphorylates and supresses 
the FoxO family of transcription factors, preventing their translocation to the nucleus and 
the expression of the two ubiquitin ligases, MAFbx/atrogin-1 and MuRF1, and autophagy 
genes. [56] Nevertheless, during catabolic diseases, this signalling pathway is silenced, and 
consequently, protein synthesis decreases whereas FoxO-mediated proteolysis (through 
FoxO-mediated expression of the atrogene programme) and fibre atrophy increases. The 
inhibition of IGF-1/PI3K/Akt/mTOR pathway can occur due to increased levels of myostatin 
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or its homologue activin A. Additionally, administration of cisplatin also decreases 
phosphorylation of the proteins Akt and mTOR. [13,57] 
 2.1.4. Myostatin pathway 
 Myostatin (also known as growth differentiation factor (GDF) 8), an 
autocrine/paracrine cytokine that negatively regulates skeletal muscle mass and growth, is 
a TGF-β-family ligand that is predominantly expressed and released by skeletal muscle. 
[16,45,73,74] Cardiac muscle and adipose tissue exhibit low levels of this molecule. This 
ligand binds to the high-affinity activin A type IIB receptor (ActRIIB) on muscle membranes, 
resulting in its assembly with the activin A type IB receptor, ALK4 or ALK5. [16,73,75] 
Consequently, the two transcription factors SMAD2 and SMAD3 are activated by 
phosphorylation, which leads to the assembly of SMAD2/3 with SMAD4. [75] This 
heterodimer is able to translocate to the nucleus and activate transcription of target genes. 
Thus, myostatin inhibits the myogenic programme, the process responsible for the 
generation of myoblasts in order to originate skeletal muscle tissue, and so myoblast 
proliferation decreases. [45,56] This means that satellite cells, the stem cells responsible 
for muscle fibres proliferation and differentiation, are inhibited. [16] In addition, protein 
synthesis decreases, due to the inhibition of the IGF-1/PI3K/Akt/mTOR pathway by 
myostatin, and therefore, the mRNA levels of MAFbx/atrogin-1 and MuRF1 increase and 
degradation-related gene expression is activated. [44,45,56] This disinhibition of FoxO also 
leads to the upregulation of autophagy genes. [70] So, protein degradation increases and 
protein synthesis decreases. [45]  
 Though the physiological and pathophysiological mechanisms that regulate 
myostatin secretion in several conditions are mostly unknown, it is known that FoxO1, NF-
κB, SMAD2, SMAD3 and SMAD4 can increase myostatin expression. [16] The released 
myostatin acts in an autocrine and paracrine manner, facilitating its catabolic effects. Other 
factors associated with TGF family members, such as activin A and GDF11, can stimulate 
SMAD2 and SMAD3 production through their binding to ActRIIB, thus acting like myostatin 
and limiting normal muscle growth and inducing muscle wasting. [16] Furthermore, 
administration of cisplatin increases the levels of phosphorylated SMAD2. [13] 
 2.1.5. NF-κB pathway   
 NF-κB is a transcription factor present in several cell types, such as in the mature 
skeletal muscle and, through the regulation of the expression of cyclin D1, inhibits 
vertebrate skeletal muscle differentiation (SMD). [76] Additionally, NF-κB is an activator of 
anti-apoptotic genes. [77] The mammalian NF-κB family is composed by five proteins – 
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RelA (p65), RelB, c-Rel, NF-κB1 (p50 and p105) and NF-κB2 (p52 and p100) - and has a 
crucial role in controlling innate and adaptive immunity. [78,79] These five proteins regulate 
the transcription of target genes by associating with each other, creating homo- and 
heterodimeric complexes, being that the p50 and p65 proteins form the principal prototypical 
heterodimer present in almost all the cell types. [78,80] Transactivation of the NF-κB can 
be started by several stimuli associated with various biological processes, for instance, 
inflammation. [55] In addition, activation of this pathway also accelerates inflammation. [12] 
Under physiological conditions, the activity of NF-κB is regulated; nevertheless, in cachexia 
this molecule is constitutively activated. [74] 
 In skeletal muscle, the potential targets of this factor are anti-apoptotic genes. [77] 
In non-stimulated cells, NF-κB proteins are present in the cytoplasm, forming a complex 
with inhibitor proteins collectively known as inhibitors of NF-κB (IκBs). [81] The majority of 
agents that activate NF-κB use a common pathway where, in a general way, occurs the 
phosphorylation of IκBs, followed by ubiquitination, and successively, degradation of IκBs 
by the proteasome. [79,81] Thus, cell stimulation leads to the activation of the IkB kinase 
(IKK) complex. [77]  This complex is constituted by two catalytic subunits, IKK-α and IKK-β, 
and a regulatory subunit, IKK-γ/NEMO. Activated IKK phosphorylates the two NH2-terminal 
serines (serine 32 and serine 36) in NF-κB-bound IκBαs, which are targeted for 
polyubiquitination and degradation. [9,77,81] The released NF-κB free dimers (p50/p65) 
translocate to the nucleus and bind to their cognate DNA-binding sites in order to regulate 
the transcriptional activation of hundred target genes, including cytokines, chemokines, 
stress response proteins and numerous enzymes, such as those related to protein 
degradation by the UPP. [77,79–81] This classic NF-κB signalling pathway is only one of 
two major pathways that activate NF-κB transcription factors. [77] The second pathway or 
alternative pathway, includes the specific activation of p52:RelB heterodimers, and it is 
required for the generation of secondary lymphoid organs and for B-cell maturation and 
survival. [77] Thus, it is not directly involved in innate immunity and inflammation, but might 
be involved in mammary carcinogenesis. Additionally, NF-κB can be activated by another 
pathway (that has a small role in the physiological NF-κB activation) independent of IKK 
that might contribute to skin carcinogenesis, given that it is activated by ultraviolet radiation. 
This pathway is based on the activation of casein kinase 2 (CK2), where IκBα degradation 
is induced by the phosphorylation of carboxy-terminal sites. [77] 
 It has been demonstrated that NF-κB is a potent inducer of myostatin, but the 
specific mechanisms by which NF-κB promotes atrophy remain undefined. [16] 
Nonetheless, increased activity of NF-κB may lead to muscle wasting possibly through three 
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potential mechanisms: i) NF-κB may improve the expression of various proteins involved in 
the UPP, which in turn, are responsible for the degradation of specific muscle proteins; ii) 
NF-κB may increase the expression of inflammatory molecules that directly or indirectly 
promote muscle wasting; iii) NF-κB may affect the myogenic differentiation process that 
may be necessary for regeneration of atrophied skeletal muscles. [80] Thus, muscle-
specific activation of NF-κB induced severe skeletal muscle atrophy similarly to the 
observed in CC. [9] Contrarily, selective blockade of NF-κB in muscle reduces the muscle 
wasting, and also, prolongs the survival in a mouse model (Lewis lung carcinoma) of CC. 
Additionally, NF-κB is involved in the deregulated activation and expansion of the satellite 
cell pool, which aggravates the wasting process. [46] This happens because satellite cells 
are incapable of complete differentiation. In addition, administration of cisplatin in healthy 
mice results in the activation of NF-κB (i.e. phosphorylation of its p65 subunit) and increases 
4-fold the NF-κB DNA binding activity in myotubes. [14] Besides that, the upstream signals 
that control NF-κB function in muscle wasting are unknown. [16]  
In cancer, as in other catabolic conditions, various pro-inflammatory cytokines such 
as TNF-α and IL-1 might induce the expression of NF-κB and, consequently, the 
upregulation of the expression of MURF1 and MAFbx/atrogin-1. [45] This pro-inflammatory 
response results particularly from the formation of p50/p65 dimers. [12] Recently, it was 
described an inflammatory cytokine named TNF-related weak inducer of apoptosis 
(TWEAK) that is strongly associated with muscle wasting. [16,54] This small pleiotropic 
cytokine is a member of the TNF-α superfamily and has several biological functions, such 
as induction of apoptosis and stimulation of pro-inflammatory cytokines. [54] This molecule 
causes NF-κB activation through binding to the surface fibroblast growth factor-inducible 14 
(Fn14) receptor. [16] Moreover, TWEAK upregulates the expression of MAFbx/atrogin-1 
and MuRF1 through the p38 MAPK and the Janus kinase/signal transducers and activators 
of transcription (JAK/STAT) pathway. Likewise, IL-6, which is secreted principally from 
tumour and immune cells, can signal through the JAK/STAT pathway, resulting in 
suppression of protein synthesis in muscle cells, since prolonged activation of this signalling 
is associated with muscle wasting observed in CC. [70,82] Until now, the efforts made to 
block a particular cytokine in order to prevent or slowdown the process of muscle wasting 
have been unsuccessful. [16,54] However, small-molecule inhibitors of IKK-β and 
suppressors of NF-κB activation have been described, but their specificity and potency are 
still uncertain. [16]  
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 2.2. Therapies applied in the management of cancer cachexia  
 There is no approved treatment for cachexia. [10] Multimodal approaches consisting 
in nutritional, metabolic and pharmacological treatments (e.g. with corticosteroids and 
progestational drugs) have been used to prevent CC; however, these therapies have not 
demonstrated to be clinically effective. [33,83] Nutritional supplements alone do not reverse 
cachexia and resistance training, which may improve lean body mass and muscle strength, 
it is not usually prescribed for cancer patients. [29] Furthermore, pharmacological 
treatments as, for example, progestational agents, are commonly used; however, besides 
merely improving fat mass, can cause adrenal insufficiency, deep vein thrombosis and 
hypogonadism. [29] Likewise, there are no approved treatment for muscle wasting. [84] 
Nevertheless, in the field of CC management, the number of clinical trials and studies is 
increasing, with several agents under investigation (Figure 3), including the neutralization 
of crucial inflammation mediators (which have the benefit of influencing multiple steps that 
are also responsible for other characteristics of cachexia, such as anorexia, pain, fatigue 
and anemia), improvement of anabolic or inhibition of catabolic signals (which may improve 
the transformed energetic pathways, resulting in a more efficient function of muscle cells). 
[44,84,85] 
 Although inflammation is a leading cause of wasting, few randomized clinical trials 
have been directed in this field. [86] Clarithromycin and thalidomide have been suggested 
as potential CC treatments, due to their anti-inflammatory properties. Treatment with 
clarithromycin significantly decreases serum levels of IL-6, increases body weight and 
increases the survival of patients with non-small cell lung cancer. [87] Treatment with 
thalidomide attenuates weight loss due to a decrease in lean body mass loss in patients 
with pancreatic cancer. [88] However, the mechanism by which this agent works is not 
known, but it is possible that results from the downregulation of pro-inflammatory cytokines, 
including TNF-α. Another proposed mechanism is the inhibition of NF-κB. [89]  
 The use of celecoxib, an oral selective cyclooxygenase-2 (COX-2) inhibitor, 
demonstrated a significant decrease in serum levels of TNF-α and increase in lean body 
mass in a phase II study. [90] Another promising approach for the treatment of CC is the 
use of an ActRIIB decoy receptor (soluble (s)ActRIIB), which is able of weight loss reversal 
and animal survival prolongation. [91] Furthermore, the inhibition of the ActRIIB pathway 
prevents the activation of key components involved in the UPP, including MAFbx/atrogin-1 
and MuRF1. ActRIIB antagonists block the SMAD2 activation and reduce the FoxO activity 
(i.e. increases FoxO phosphorylation), suggestive of IGF-1/PI3K/Akt/mTOR pathway 
activation. Moreover, myostatin neutralizing antibody can attenuate skeletal muscle mass 
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Figure 3. Possible therapeutic approaches for cachexia and muscle wasting. Ghrelin administration 
increases appetite and muscle mass. Clarithromycin decreases serum levels of interleukin 6 (IL-6), improving 
the cachectic status. Regarding thalidomide, this agent attenuates weight loss, possible (?) through 
downregulation of pro-inflammatory cytokines, such as tumour necrosis factor alpha (TNF-α) and /or through the 
inhibition of prototypical nuclear factor kappa light-chain-enhancer of activated B cells (NF-κB). In addition, the 
use of celecoxib demonstrated a significant decrease in serum levels of TNF-α and increase in lean body mass. 
The use of an activin A type IIB receptor (ActRIIB) decoy receptor (sActRIIB), results in the inhibition of the 
myostatin pathway, and also, prevents the activation of muscle atrophy F-box protein (MAFbx/atrogin-1) and 
muscle-specific RING-finger 1 (MuRF1). In addition, activate the insulin-like growth factor 1 (IGF-
1)/phosphatidylinositol-3-kinase (PI3K)/Akt (also known as PKB – protein kinase B)/mammalian target of 
rapamycin (mTOR) pathway, thus preserving muscle mass. Resveratrol and the nemo-binding domain (NBD) 
peptide are inhibitors of the NF-κB pathway, and so, decrease the expression of MuRF1 and MAFbx/atrogin-1. 
Finally, the eicosapentaenoic acid (EPA), decreases pro-inflammatory cytokines release and inhibit NF-κB. 
   
21 
 
loss, both alone and in the context of chemotherapy. [92] In this perspective, restoration of 
the expression of sirtuin 6 (SIRT6) may be useful as a new therapeutic approach to diminish 
muscle wasting associated with chronic diseases since, under physiological condition, this 
molecule negatively regulates myostatin expression, possible through inhibition of the NF-
κB signalling, promoting myogenesis. [74] Studies have been made in order to evaluate the 
use of agents that inhibit the nuclear translocation of NF-κB in the treatment of muscle 
wasting in CC. [93] In fact, resveratrol, an inhibitor of IKK, significantly decreases the NF-
κB DNA-binding activity and significantly attenuates body weight loss and tumour growth 
rate. In addition, the administration of curcumin and rutin, which also inhibit NF-κB 
signalling, had a protective effect on muscle, improving survival and reducing inflammation 
[94]. Additionally, the treatment with the nemo-binding domain (NBD) peptide, a competitive 
inhibitor of the IKK complex, resulted in an increase in lean body and fat mass, through the 
inhibition of skeletal muscle NF-κB signalling and the decreased expression of MuRF1 and 
MAFbx/atrogin-1 in tumour-bearing mice, without evidences of toxicity to the liver or kidney. 
[95] Dimethylaminoparthenolide (DMAPT), which is the orally bioavailable analogue of 
parthenolide, a sesquiterpene lactone isolated from the medicinal herb feverfew, was also 
reported to inhibit the NF-κB activity and to present anti-inflammatory properties, and so, it 
seems to be a promising agent to counteract the wasting process. [96,97] 
 One of the most promising potential therapeutic option proposed for CC is an 
endogenous ligand for the growth hormone (GH) secretagogue receptor (GHS-R1a), 
named ghrelin. [10,29] Ghrelin, but also ghrelin receptor agonists, may improve muscle 
mass, strength, anorexia and weight loss in cancer patients, principally those receiving 
cisplatin-based chemotherapy. This 28-amino acid peptide, which contains a n-octanoyl 
modification on Ser3 (i.e. biologically active), is produced, mainly, by the oxyntic cells of the 
stomach and it is a potent GH secretagogue (GHS). [32,83,98,99] Ghrelin administration 
increases appetite, fat and muscle mass, but mechanistically, the action of this hormone is 
not fully understood. [29] In other words, until now, it is not known if the antagonistic effect 
of ghrelin on weight loss induced by cisplatin is a consequence of the direct stimulatory 
effect of the hormone on hypothalamic neurons (where the GHS-R1a is present; more 
precisely on the arcuate nucleus) that regulate the appetite and/or of the indirect effect 
mediated by ghrelin’s prokinetic properties (i.e. enhancement of gastrointestinal motility that 
may contribute to reduce the nausea and vomiting). [32,100] Nevertheless, it is thought that 
the effects produced by ghrelin administration are mediated by: i) an increase in food intake 
through the activation of the GHS-R1a in specific hypothalamic neurons; ii) a decrease in 
energy expenditure, also throughout hypothalamic effects, particularly by suppressing the 
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sympathetic nerve system output to brown adipose tissue, thus decreasing thermogenesis; 
iii) stimulation of GH release; iv) reduction of inflammation; v) direct effects in skeletal 
muscle and adipose tissue. [10,29,32,100] In fact, administration of ghrelin prevents the 
increased activation of the proteasome, as well as, the myostatin up-regulation. 
Furthermore, administration of ghrelin prevents the decrease in IGF-1 levels, being that 
both ghrelin and GHS promote the release of GH, resulting in an increase in the hepatic 
production of IGF-1. This increase in the levels of IGF-1 is related to an increase in protein 
synthesis and a decrease in proteolysis, thus possibly contributing to the preservation of 
muscle mass. [32,100] In addition, ghrelin prevents the increase in the levels of 
phosphorylated p38 and pro-inflammatory cytokines (e.g. TNF-α, IL-6 and IL-1β). [29,32] 
As a matter of fact, these cytokines and ghrelin have antagonistic effects on appetite and 
body weight. [98,100] Cytokines may directly decrease ghrelin production through the 
activation of anorexigenic pathways that lead to a reduction in food intake. In the other hand, 
ghrelin may supress TNF-α and IL-6 production, via the central inhibition of the inflammatory 
process. In addition, the administration of ghrelin stabilizes weight loss during treatment 
with cisplatin and induces a rapid weight gain after it. [32] Interestingly, in cancer-induced 
cachexia, active ghrelin levels are elevated and the same occurs after cisplatin 
administration, which suggests that resistance to the orexigenic effects of the endogenous 
ghrelin might occur. [32,98] However, this resistance should be partial, since further 
elevation in ghrelin levels in 3- to 4- fold from the baseline, seems to increase appetite and 
food intake. [98] Thus, various synthetic GHS have been developed and are presently in 
study for the treatment of CC. [100] Similarly, the synthetic and orally active orexigenic 
progestational agents megestrol acetate and medroxyprogesterone acetate have also been 
shown to improve food intake, promoting weight gain [12,44]. In addition, they decrease 
pro-inflammatory cytokines levels, including TNF-α, IL-1 and IL-6 [12]. The mechanism of 
action of these drugs is unknown and, unfortunately, they exhibit several limitations [44,86]. 
For example, the weight gain obtained is habitually composed of fat, and besides that, these 
drugs have a significant glucocorticoid character, promoting muscle wasting. Moreover, 
these agents are expensive, contraindicated in patients with hormone-sensitive diseases 
and have side-effects, including impotence in males [86]. 
  The nutritional approach through the integration of formulated nutrient mixtures in 
the diet not only provides energy and protein but also counteracts CC-related inflammation. 
[53] Oral supplementation with eicosapentaenoic acid (EPA), an ω-3 polyunsaturated fatty 
acid present in fish oil, significantly decreases the weight loss rate in patients with advanced 
pancreatic cancer. [101,102] It is suggested that this effect is due to a decrease in pro-
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inflammatory cytokine release and NF-κB inhibition. Likewise, docosahexaenoic acid has 
been studied as a therapeutic approach to CC. [53] In addition, branched chain amino acids 
(e.g. leucine, isoleucine and valine) have been shown to increase protein synthesis and 
decrease protein degradation in skeletal muscle, thus having a protective effect on muscle 
mass. [103]  
 Exercise training has been suggested to integrate the multimodal treatment 
approach to CC. [53] In fact, exercise may modulate skeletal muscle metabolism and 
inflammation. Treadmill exercise was reported to attenuate cisplatin-induced up-regulation 
of MuRF1 and MAFbx/atrogin-1 in a mouse model. [104] Voluntary wheel running also 
prevented lean body mass loss in cisplatin-treated mice, by abolishing the cisplatin-induced 
expression of MuRF-1, MAFbx/atrogin-1 and IL-6, as well as the repression of Akt and 
mTOR. [57] However, exercise training interventions are normally difficult to implement in 
the set of cancer since there are several factors that might limit the exercise capacity (e.g. 
anemia and chronic fatigue). [104] 
  Finally, the potential therapeutic approaches against muscle wasting should: i) 
modulate the expression or activity of circulating factors that induce the UPP and/or the NF-
κB (e.g. TNF-α or IL-6), that inhibit muscle growth (e.g. myostatin) or that promote muscle 
hypertrophy (e.g. insulin or IGF-1); ii) target intracellular effectors involved in muscle 
wasting, including the NF-κB pathway or the transcription factor FoxO; and directly inhibit 
the UPP. [85] However, a limitation of the efforts to reduce muscle wasting is that the 
targeted molecules are not muscle-specific, and so, modification of their activity or 
expression may be related to side-effects that might deteriorate the clinical status of the 
patient. Thus, a possible strategy that could help to improve treatment is a combination of 
drugs with synergistic effects, allowing the use of sub-therapeutic doses of each drug and 
so decrease the possibility of injurious side-effects. Another strategy is the development of 
compounds that have as targets specific key factors involved in muscle wasting and that 
have no general functions outside the skeletal muscle. For instance, the E3s specifically 
induced during muscle wasting, such as MuRF-1, are potential options. Accordingly, the 
disruption of the interaction between the E3s and its substrate(s) may be the key to obtain 
specific and efficient inhibitors of the E3s. However, information such as the nature of the 
relevant substrates of the E3s and the structure of the E3-substrate pair to be targeted are 
not currently available. [33] 
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 The general aim of the present dissertation was to study the effect of the widely-
used chemotherapeutic agent cisplatin on the skeletal muscle remodelling, and 
simultaneously, the putative therapeutic role of the natural compound DMAPT, since it can 
inhibit the NF-κB pathway and has anti-inflammatory properties. To accomplish this aim, 
two studies were made. In study 1, it was evaluated the effect, in healthy animals, of an 
acute administration of cisplatin on inflammatory mediators and signalling pathways that 
regulate the skeletal muscle mass and the influence of DMAPT on that effect. Concerning 
the study 2, it was ascertained, in the urothelial-carcinoma context, the effect of chronic 
administration of cisplatin alone and in combination with DMAPT on serum markers of 
catabolism. 
 
 
 
 
 
 
 
 
 
 
 
 
  
III. MATERIALS AND METHODS 
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1. CHEMICALS 
Cisplatin was purchased from TEVA Pharma (Porto Salvo, Portugal), DMAPT was 
kindly provided by Professor Christopher Sweeney (Dana-Farber Cancer Institute, Boston, 
EUA) and N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) was acquired from Tokyo Kasei 
Kogyo (Tokyo, Japan). All other reagents and chemicals used were of highest grade of 
purity commercially available. Rabbit polyclonal anti-NF-κB p65 (ab16502), rabbit 
monoclonal anti-NF-κB p105/50 (ab32360), rabbit polyclonal anti-MuRF-1 (ab77577), rabbit 
polyclonal anti-myostatin (ab98337), mouse monoclonal anti-adenosine triphosphate (ATP) 
synthase (ab14730), rabbit polyclonal anti-glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (ab9485), rabbit polyclonal anti-IL-6 (ab6672), rabbit polyclonal anti-C reactive 
protein (CRP) (ab65842), rabbit polyclonal anti-ghrelin (ab64325), rabbit polyclonal anti-
TWEAK (ab37170), rabbit polyclonal anti-metalloproteinase (MMP) 2 (ab37150) and rabbit 
polyclonal anti-MMP9 (ab38898) were acquired from Abcam® (Cambridge, UK). Rabbit 
polyclonal anti-atrogin-1 (AP2041) was acquired from ECM Biosciences (Versailles, 
Kentucky) and rabbit monoclonal anti-phospho-IκBα (#2859S) from Cell Signaling 
Technology (MA, USA). Anti-rabbit and anti-mouse horseradish peroxidase secondary 
antibodies (NA934V and NA931V, respectively) were purchased from GE Healthcare (UK). 
2. EXPERIMENTAL PROCEDURES 
In order to accomplish the proposed aims for this dissertation, the experimental 
methodology illustrated in Figure 4 was followed. This research was divided in two studies: 
in study 1 we evaluated the skeletal muscle remodelling induced by an acute administration 
cisplatin and related with the pro-inflammatory and catabolic cytokines profile in serum and 
the role of DMAPT on these effects; in study 2 focus was given to serum alterations induced 
by chronic administration of cisplatin in cancer animals and also the effect of DMAPT on 
these alterations. All methods are clarified in the following sub-sections. 
 2.1. Animals 
 In study 1, six weeks-old female CD1-mice were divided in three experimental 
groups with five animals each: control, cisplatin and cisplatin plus DMAPT. The animals 
treated with cisplatin were intraperitoneally (i.p.) injected with 10 mg.kg-1 of the drug at day 
zero, whereas 100 mg.kg-1 of DMAPT was administered orally and daily, starting at day -1, 
in the respective animals. Mice were sacrificed after two weeks. Regarding study 2, an 
immune-competent mouse model of muscle-invasive (T2) bladder cancer induced by the 
tobacco-related agent BBN was used. Six weeks-old female CD-1 mice were utilized. The 
animals were divided in five experimental groups: control (n=15), BBN (n=19), BBN and 
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cisplatin-treated (n=18), BBN and DMAPT-treated (n=17) and BBN and the combination of 
cisplatin plus DMAPT (n=19). In the groups treated with cisplatin the animals were 
administered i.p. with 4.0 mg.kg-1 weekly, while the mice treated with DMAPT received 100.0 
mg.kg-1 daily, for six weeks. All the procedures followed the 2010/63/EU animal welfare 
directive. In the day before the sacrifice, forelimb grip strength test was performed to 
evaluate muscle force using a grip strength meter, as previously reported. [105] 
Figure 4. Schematic figure representing the experimental procedures performed in the (A) study 1 and (B) study 
2. In study 1 the animals were divided in three groups – control (n=5), cisplatin (n=5) and cisplatin + 
dimethylaminoparthenolide (DMAPT) (n=5) –, whereas the study 2 was constituted by five experimental groups 
– control (n=15), N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) (n=19), BBN + cisplatin (n=18), BBN + DMAPT 
(n=17), BBN + cisplatin + DMAPT (n=19). In both studies serum analysis was done through slot blot assays,  
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 2.2. Gastrocnemius muscle preparation and analysis 
A portion of approximately 50 mg of gastrocnemius muscle was homogenized in 1 
mL of 100 mM phosphate buffer (50 mM KH2PO4, 0.5% Triton X-100 and 200 mM PMSF), 
using a Teflon pestle on a motor-driven Potter-Elvehjem glass homogenizer. The obtained 
samples were preserved at -80ºC for biochemical analysis. 
 2.2.1. Total protein quantification 
The protein content in the gastrocnemius muscle samples was assayed with the 
commercial kit DCTM Protein Assay (Bio-Rad®, CA, USA), according to the manufacture’s 
recommendations and using bovine serum albumin (BSA) as a standard. Briefly, to 5 μL of 
gastrocnemius muscle homogenate or BSA standards was added 25 μL of reagent A’ 
(prepared by the addition of 1 mL of reagent A and 20 μL of reagent S) and 200 μL of reagent 
B. After 15 minutes at room temperature, the absorbance was measured at 750 nm in a 
microplate reader (Multiskan GO, Thermo Fischer Scientific®, Northumberland, UK).  
 2.2.2. Spectrophotometric assay of citrate synthase activity 
The citrate synthase activity was determined according to Coore and collaborators 
[106]. Firstly, the reaction mixture composed by 200 mM Tris pH 8.0, 10 mM acetyl-CoA, 
10 mM 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) and 0.1% (v/v) Triton X-100 was 
prepared. Secondly, to 5 μL of each sample was added 190 μL of the reaction mixture and 
the absorbance was read at 412 nm for approximately 2 minutes at 30ºC. Thirdly, 4 μL of 
10 mM oxaloacetate was added to each well of the microplate and the absorbance was 
again read at 412 nm for approximately 2 minutes at 30ºC. Fourthly, the absorbance values 
of the second phase of readings for each well were plotted against time, being the slope of 
the equation (∆Absorbance412/min) divided by the molar absorption coefficient, at 412 nm, 
of the mercaptide ion formed (13.6 mM-1.cm-1). Finally, the acquired values were divided by 
the total protein content of each sample, obtaining the citrate synthase activity. 
while western blot analysis, zymography and spectrophotometric assay were only conducted in study 1 in order 
to analyse the gastrocnemius muscle. The proteins analysed are below the corresponding assays. Legend: ATP: 
adenosine triphosphate | CRP: C reactive protein | GAPDH: glyceraldehyde 3-phosphate dehydrogenase | IκBα: 
inhibitors of NF-κB | IL-6: interleukin-6 | MAFbx/atrogin-1: muscle atrophy F-box protein | MMP: metalloproteinase 
| MuRF1: muscle-specific RING-finger 1 | NF-κB: prototypical nuclear factor kappa light-chain-enhancer of 
activated B cells | TWEAK: tumour necrosis factor-related weak inducer of apoptosis. Figure produced using the 
Servier Medical Art. 
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 2.2.3. Western blot analysis 
Certain volumes of gastrocnemius muscle samples equivalent to 50 μg of protein 
were diluted 1:1 (v/v) in reduction buffer (0.5 M Tris-HCl pH 6.8, 4% (w/v) SDS, 15% (v/v) 
glycerol, 0.04% (w/v) bromophenol blue and 20% (v/v) β-mercaptoethanol) and incubated 
at 100 ºC for 5 minutes, followed by electrophoresis on a 12.5% sodium dodecyl sulphate- 
-polyacrylamide gel electrophoresis (SDS-PAGE) (prepared according to Laemmli [107]) 
during 45 minutes at 180 V in running buffer (25 mM Tris, 192 mM glycine and 0.1% (w/v) 
SDS). Then, the gels were blotted onto a nitrocellulose membrane (Amersham™, Protan®, 
GE Healthcare) in transfer buffer (25 mM Tris, 192 mM glycine and 20% methanol) during 
2 hours at 200 mA. After this process, protein loading was controlled by Ponceau S staining. 
Nonspecific binding was blocked in 5% (w/v) nonfat dry milk in TBS-T (100 mM Tris pH 8.0, 
1.5 M NaCl and 0.5% Tween 20) during 1 hour at room temperature with agitation. Then, 
the membranes were incubated with the corresponding primary antibody [anti-NF-κB p65, 
anti-NF-κB p105/50, anti-MuRF-1, anti-atrogin-1, anti-TWEAK, anti-GAPDH, anti-ATP 
synthase and anti-phospho IκBα (diluted 1:1000 in 5% (w/v) nonfat dry milk in TBS-T)] for 
2 hours at room temperature and with agitation. After this, the membranes were washed 3 
times (10 minutes each) with TBS-T, followed by incubation with anti-rabbit or anti-mouse 
peroxidase secondary antibody (diluted 1:1000 in 5% (w/v) nonfat dry milk in TBS-T) for 2 
hours at room temperature with agitation. Then, the membranes were again washed 3 times 
with TBS-T (10 minutes each). Lastly, immunoreactive bands were detected with enhanced 
chemiluminescence (ECL) reagents (WesternBright™ ECL, advansta, CA, USA) according 
to the manufacturer’s procedure. Images were recorded using X-ray films (Amersham™ 
Hyperfilm™ ECL, GE Healthcare), which were scanned using Gel Doc XR system (Bio-
Rad®, CA, USA) and analysed with Image Lab software (Bio-Rad®, CA, USA, version 
6.0.0,). The optical densities obtained were expressed in arbitrary units. 
 2.2.4. Gelatine zymography 
Certain volumes of gastrocnemius muscle samples equivalent to 50 μg of protein 
were incubated on charging buffer (100 mM Tris pH 6.8, 5% SDS, 20% glycerol and 0.1% 
bromophenol blue) for 10 minutes at room temperature, in a proportion of 1:1 (v/v), followed 
by electrophoresis. In this procedure, a 10% SDS-PAGE separation gel with 0.1% of gelatin 
was used and the gels were run during 1 hour at 125V. Then, the gels were incubated in 
renaturation buffer (2.5% Triton X-100) for 1 hour at room temperature and with agitation, 
followed by incubation in development buffer (50 mM Tris pH 8.8, 5 mM NaCl, 10 mM CaCl2, 
1 μM ZnCl2, pH 7.4, 0.02% (v/v) Triton X-100) for 30 minutes at room temperature and with 
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agitation. Immediately after this, the gels were again incubated in a new development buffer, 
but now overnight and at 37ºC. The zymography gels were then stained with a solution of 
Coomasie Brilliant Blue G250 (0.4% (w/v) Coomassie Brilliant Blue, 50% (v/v) ethanol and 
10% (v/v) acetic acid), during 3 hours at room temperature and with agitation. Lastly, the 
gels were destained with 25% (v/v) ethanol and 5% (v/v) acetic acid with two changes of 
the solution. The gels were scanned using Gel Doc XR system (Bio-Rad®, CA, USA) and 
analysed with Image Lab software (Bio-Rad®, CA, USA, version 6.0.0). The optical densities 
obtained were expressed in arbitrary units. 
 2.3. Serum sample analysis 
In order to analyse biochemical parameters in serum samples, 10 μL of each sample 
was diluted in 490 μL TBS 1x (10 mM Tris, pH 8.0, 0.15 M NaCl). Then, 50 μL of each of 
these samples were blotted onto a nitrocellulose membrane (Amersham™, Protan®, GE 
Healthcare), followed by Ponceau S staining for protein loading control. Nonspecific binding 
was blocked with 5% (w/v) nonfat dry milk in TBS-T, during 1 hour at room temperature with 
agitation. The membranes were incubated with the corresponding primary antibody [anti-
IL-6, anti-TWEAK, anti-ghrelin, anti-CRP, anti-myostatin, anti-MMP2 and anti-MMP9 
(diluted 1:1000 in 5% (w/v) nonfat dry milk in TBS-T)] for 1 hour at room temperature and 
with agitation. After this time, the membranes were washed 3 times (10 minutes each) with 
TBS-T and incubated with anti-rabbit peroxidase secondary antibody (diluted 1:1000 in 5% 
(w/v) nonfat dry milk in TBS-T) for 1 hour at room temperature with agitation. Membranes 
were then washed 3 times with TBS-T (10 minutes each). Immunoreactive bands were 
detected with ECL reagents (WesternBright™ ECL, advansta, CA, USA) according to the 
manufacturer’s procedure. Images were recorded using X-ray films (Amersham™ 
Hyperfilm™ ECL, GE Healthcare), which were scanned using Gel Doc XR system (Bio-
Rad®, CA, USA) and analysed with Image Lab software (Bio-Rad®, CA, USA, version 
6.0.0,). The optical densities obtained were expressed in arbitrary units.  
 2.4. Statistical analysis 
Values are presented as mean ± standard deviation for each experimental group. 
The statistical significance of the differences between the experimental groups was 
determined using a one-way analysis of variance (ANOVA) followed by the Turkey multiple 
comparisons post hoc test. Results were considered significantly different when p<0.05. 
These statistical analyses were performed with the GraphPad Prism® software for windows 
(version 6.01). 
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1. THE EFFECT OF CISPLATIN OR CISPLATIN PLUS DMAPT ON CATABOLIC 
PHENOTYPE 
In study 1 were evaluated anthropometric, serum and skeletal muscle alterations 
induced by cisplatin or cisplatin plus DMAPT administration on healthy mice. The results of 
these analyses are described in the following sub-sections. 
 1.1. Characterization of animals’ response to cisplatin or cisplatin plus DMAPT 
Description of the animals used in this study concerning body weight, gastrocnemius 
muscle weight, spleen weight, kidney weight and gastrocnemius-to-body weight, spleen-to-
body weight and kidney-to-body weight ratios is reported in Table 1. Administration of 
cisplatin plus DMAPT caused a significant reduction of body weight, when compared with 
the animals that received only cisplatin (p<0.01). Nevertheless, no significant differences 
were observed between groups on the gastrocnemius muscle weight; however, cisplatin 
and DMAPT exposure caused a significant increase of the ratio gastrocnemius-to-body 
weight when compared to the control (p<0.05) and cisplatin (p<0.01) groups, suggestive of 
muscle hypertrophy. Concerning the spleen, the animals treated with the combination of 
cisplatin and DMAPT had a significant decrease in its weight, when compared with the 
control (p<0.01) and cisplatin (p<0.05) groups; nonetheless, when the ratio between the 
spleen and the body weight is analysed, it is observed a significant decrease on the cisplatin 
plus DMAPT group only when compared with the control one (p<0.01). In addition, 
administration of cisplatin plus DMAPT reduced the kidney weight, comparing to the control 
and cisplatin groups (p<0.01) and the same occurred to the kidney-to-body weight ratio 
(p<0.01 vs. control and p<0.05 vs. cisplatin). 
 
 Experimental groups 
 Control Cisplatin Cisplatin + DMAPT 
Body weight (g) 30.51 ± 2.19 32.92 ± 2.32 ** 27.22 ± 2.05 
Gastrocnemius muscle weight (g) 0.256 ± 0.008 0.267 ± 0.034 0.260 ± 0.019 
Gastrocnemius-to-body weight 
(mg.g
-1
) 
8.43 ± 0.50 * 8.08 ± 0.62 ** 9.57 ± 0.57 
Spleen weight (g) 0.195 ± 0.054 ** 0.156 ± 0.022 * 0.090 ± 0.026 
Spleen-to-body weight (mg.g
-1
) 6.35 ± 1.66 ** 4.72 ± 0.48 3.27 ± 0.74 
Kidney weight (g) 0.580 ± 0.088 ** 0.588 ± 0.055 ** 0.404 ± 0.074 
Kidney-to-body weight (mg.g-1) 19.0 ± 1.7 ** 17.8 ± 0.9 * 14.7 ± 1.7 
Table 1. The effect of cisplatin or cisplatin plus DMAPT on body weight, gastrocnemius muscle weight, spleen 
weight and kidney weight and on the ratios gastrocnemius-to-body weight, spleen-to-body weight and kidney-
to-body weight. Values are expressed as mean ± standard deviation. 
 
** p < 0.01 vs. cisplatin + DMAPT and * p < 0.05 vs. cisplatin + DMAPT 
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The results of serum analysis are depicted in Figure 5. Cisplatin plus DMAPT 
administration caused a reduction in CRP levels, comparing with the cisplatin group 
(p<0.05, Figure 5. A). Likewise, cisplatin plus DMAPT administration caused a significant 
reduction of TWEAK serum levels, but when compared to the control group (p<0.05, Figure 
5. B). Regarding IL-6 (Figure 5. C) or ghrelin (Figure 5. D) circulating levels no significant 
differences were observed between groups. 
 1.2. Analysis of the gastrocnemius muscle response to cisplatin or cisplatin 
plus DMAPT administration 
The metabolic profile of gastrocnemius from each of the experimental groups in 
study is represented in Figure 6. No significant differences were observed between groups 
on ATP synthase (Figure 6. A) or GAPDH (Figure 6. B) levels, nor ATP synthase/GAPDH 
ratio (Figure 6. C). Likewise, no differences were observed in the activity of citrate synthase 
(Figure 6. D). So, the therapies studied seem to have no impact on the metabolic phenotype 
of gastrocnemius. 
Figure 5. Effect of cisplatin or cisplatin plus DMAPT administration on (A) CRP, (B) TWEAK, (C) IL-6 and (D) 
ghrelin serum levels. Representative immunoblots are presented above the corresponding graphs. Values are 
expressed as mean ± standard deviation. (* p<0.05) 
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The TWEAK/NF-κB axis was also studied, considering the expected effect of 
DMAPT on NF-κB signalling, [96,108] and the results are depicted in Figure 7. Regarding 
TWEAK (Figure 7. A), it was observed in the animals exposed to the combination of cisplatin 
and DMAPT a significant increase in its expression, when compared to the cisplatin group 
(p<0.05). Administration of cisplatin plus DMAPT also caused a significant increase in the 
expression of the subunit p105/50 of NF-κB, relatively to the cisplatin group (p<0.05, Figure 
7. B). However, no differences were observed in the levels of the subunit p65 of NF-κB 
(Figure 7. C) or in the levels of the inhibitor IκBα (Figure 7. D). So, DMAPT seems to induce 
the formation of p50 homodimers in the gastrocnemius muscle, possibly through the 
TWEAK-induced activation of Fn14.  
Figure 6. Effect of cisplatin or cisplatin plus DMAPT administration on the muscle expressions of (A) ATP 
synthase and (B) GAPDH. Representative immunoblots are presented in (C). It is also presented the (D) ATP 
synthase/GAPDH ratio. In (E) the citrate synthase activity can be observed. The values are expressed as mean 
± standard deviation. 
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Concerning the proteolytic activity, the results obtained can be observed in Figure 
8. No significant differences were observed between the experimental groups in the levels 
of MuRF1 (Figure 8. A) or MAFbx/atrogin-1 (Figure 8. B). Nevertheless, the analysis of the 
zymography gel (Figure 8. C) evidenced a significant reduction of the activity of the band 
with 72 kDa (which is predicted to be MMP2 according to Uniprot) in cisplatin plus DMAPT 
group, comparing with the cisplatin one (p<0.05, Figure 8. D). It was also analysed the 
myostatin expression by western blotting to evaluate its putative contribution to muscle 
catabolism, but no signal was detected in the blots. 
 
Figure 7. Effect of cisplatin or cisplatin plus DMAPT administration on the muscle expressions of (A) TWEAK, 
(B) NF-κB p105/50, (C) NF-κB p65 and (D) IκBα. Representative immunoblots are presented in (E). The values 
are expressed as mean ± standard deviation. (* p<0.05) 
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2. THE EFFECT OF CISPLATIN, DMAPT OR CISPLATIN PLUS DMAPT ON BLADDER 
CANCER-INDUCED ANIMALS 
In study 2, the effect of cisplatin, DMAPT or the combination of these two agents in 
animals’ anthropometric parameters and serum profile was explored. During the protocol, 
one DMAPT-treated and one cisplatin-treated mouse died. 
Figure 8. Effect of cisplatin or cisplatin plus DMAPT administration on the muscle expression of (A) MuRF1 and 
(B) MAFbx/atrogin-1. Representative immunoblots are presented in (C). (D) Representative zymography gel, 
evidencing one band with proteolytic activity. In (E) is presented the semi-quantitative analysis of the proteolytic 
activity for each group. The values are expressed as mean ± standard deviation. (* p<0.05) 
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 2.1. Characterization of animals’ response to cisplatin, DMAPT or cisplatin 
plus DMAPT administration 
In Table 2 is reported the description of the animals used in this study concerning 
body weight, gastrocnemius muscle weight, spleen weight and gastrocnemius-to-body 
weight and spleen-to-body weight ratios. In cancer-induced animals exposed to cisplatin or 
cisplatin plus DMAPT occurred a reduction on body weight, comparatively to BBN animals 
(p<0.0001) and to the control ones (p<0.0001 vs. BBN + Cisplatin and p<0.001 vs. BBN + 
Cisplatin + DMAPT). Contrarily, in BBN animals administered with DMAPT occurred an 
increase of body weight, comparing with BBN plus cisplatin (p<0.0001) or BBN plus cisplatin 
plus DMAPT (p<0.001) animals. Regarding gastrocnemius muscle, in both BBN plus 
cisplatin animals or BBN plus cisplatin plus DMAPT animals a significant decrease in this 
muscle weight occurred, comparing to the control ones (p<0.05). Nevertheless, no 
significant differences were observed in the gastrocnemius-to-body weight ratio. Regarding 
the spleen, when comparing the BBN plus cisplatin group with the control (p<0.01) or BBN 
groups (p<0.0001) it is observed a significant weight decrease. Likewise, in BBN plus 
cisplatin plus DMAPT animals a decrease on spleen weight was observed, comparing with 
the control (p<0.05) or BBN (p<0.01) or BBN plus DMAPT (p<0.01) ones. Concerning 
spleen-to-body weight ratio, a significant decrease was observed in BBN plus cisplatin-
treated animals comparing with the BBN plus DMAPT littermates (p<0.05).  
 
 Experimental groups 
 Control BBN 
BBN + 
Cisplatin 
BBN + 
DMAPT 
BBN + Cisplatin  
+ DMAPT 
Body weight (g) 33.9 ± 3.2 
a,c
 34.8 ± 3.5 27.3 ± 3.6 
b
 33.8 ± 2.5 
a,c
 28.6 ± 4.5 
b
 
Gastrocnemius muscle 
weight (g) 0.207 ± 0.037 0.188 ± 0.048 0.152 ± 0.046 
f
 0.193 ± 0.046 0.157 ± 0.051 
f
 
Gastrocnemius-to-body 
weight (mg.g
-1
) 5.18 ± 0.83 5.38 ± 1.25 5.23 ± 1.46 5.07 ± 1.32 5.08 ± 1.83 
Spleen (g) 0.127 ± 0.031 
d
 0.137 ± 0.026 
e,a
 0.085 ± 0.035 0.138 ± 0.036 
e,a
 0.096 ± 0.030 
f
 
Spleen-to-body weight 
(mg.g
-1
) 3.77 ± 1.03 3.95 ± 0.76 3.14 ± 1.22
g
 4.08 ± 1.04 3.32 ± 0.72 
a p<0.0001 vs. BBN + Cisplatin; b p<0.0001 vs. BBN; c p<0.001 vs. BBN + Cisplatin + DMAPT; d p<0.01 vs. BBN + Cisplatin; 
e p<0.01 vs. BBN + Cisplatin + DMAPT; f p<0.05 vs. control; g p<0.05 vs. BBN + DMAPT 
Table 2. The effect of cisplatin or DMAPT or the combination of cisplatin plus DMAPT on body weight, 
gastrocnemius muscle weight, spleen weight and the ratios gastrocnemius-to-body weight and spleen-to-body 
weight. Values are expressed as mean ± standard deviation. 
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 In Table 3 is depicted the percentage of lesions observed in the animals (bladder 
tissue examination was performed by veterinarian pathologists). BBN-induced animals or 
BBN plus cisplatin or BBN plus DMAPT treated ones showed invasive and muscle invasive 
lesions, whereas in the control or BBN plus cisplatin plus DMAPT groups no lesions were 
observed. 
Table 3. Characterization of the experimental groups used in study 2 concerning the percentage of invasive and 
muscle invasive lesions. 
 
It was also performed a grip strength test and the results are presented in Figure 9. 
No significant differences were observed between groups concerning the grip strength 
(Figure 9. A) or the grip strength-to-body weight ratio (Figure 9. B), suggesting that the 
conditions in study did not induced muscle fatigue. 
The results of serum analysis are depicted in Figure 10. No significant differences 
were observed in CRP (Figure 10. A), ghrelin (Figure 10. C), myostatin (Figure 10. D), 
MMP2 (Figure 10. E) or MMP9 (Figure 10. F) circulating levels. Regarding IL-6 content, a 
significant increase occurred in the BBN-treated animals that received cisplatin, when 
compared to the control ones (p<0.05, Figure 10. B).  
 
 Experimental groups 
 Control BBN BBN + Cisplatin BBN + DMAPT BBN + Cisplatin + DMAPT 
Invasive lesions (%) 0.00 42.1 11.1 35.3 0.00 
Muscle invasive lesions (%) 0.00 15.8 5.6 17.6 0.00 
Figure 9. Effect of cisplatin or DMAPT or cisplatin plus DMAPT administration on the (A) grip strength or (B) 
grip strength-to-body weight ratio of BBN animals. The values are expressed as mean ± standard deviation. 
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Figure 10. Effect of cisplatin or DMAPT or cisplatin plus DMAPT administration on the serum levels of (A) CRP, 
(B) IL-6, (C) ghrelin, (D) myostatin, (E) MMP2 or (F) MMP9. Representative immunoblots are presented above 
the corresponding graphs. The values are expressed as mean ± standard deviation. (* p<0.05) 
 
 
 
 
 
 
V. DISCUSSION 
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More than 50% of cancer patients are affected by CC, characterized by a weight 
loss of at least 5% in 3 to 6 months or a body mass index (BMI) of <20.0 kg.m-2. [109,110] 
The presence of an inflammatory state is frequently related with this condition, which is 
partly responsible for the increased muscle protein breakdown that leads to the severe and 
involuntary skeletal muscle loss observed in these patients. [61,110] It is important to notice 
that to a poor prognosis it is directly linked the colossal loss of skeletal muscle mass and 
that it is why it is considered the main hallmark of CC. [109] In fact, nearly 80% of patients 
with cancer suffering cachexia will be dead within 1 year post-diagnosis. [61] Furthermore, 
this multifactorial syndrome is accompanied by a reduction in the tolerance and 
effectiveness of anti-cancer treatments, increasing morbidity and further impairing the 
quality of life and survival of these patients. [109,110] In turn, chemotherapy, which is widely 
used in cancer treatment, might per se induce muscle wasting, thus exacerbating cachexia. 
[111] Unfortunately, conventional nutritional support cannot completely reverse the 
syndrome, since weight stabilization does not avoid the continuing loss of skeletal muscle 
mass or correct the related abnormal metabolic profile. [109,110] So, to prevent the wasting 
process it is necessary the implementation of mechanism-based therapeutic agents, but the 
poor knowledge of the underlying molecular mechanisms constitutes a problem. [109] Thus, 
treatments directed to muscle or inflammatory pathways may possibly be effective in 
decreasing the devastating effects of cachexia. [110]  
One natural compound that has been studied as a potential therapy for wasting 
conditions is DMAPT, because it is capable of inhibiting the NF-κB pathway and presents 
anti-inflammatory effects, which are mechanisms responsible for CC. [70,108,112] Since 
other drugs targeting inflammation and the NF-κB pathway has been ascertained to 
counteract or reduce the devastating effects of CC, DMAPT seems a promising therapeutic 
approach for muscle wasting. [113,114] With these ideas in mind, we investigated the effect 
on the skeletal muscle of the widely-used chemotherapeutic agent cisplatin in healthy and 
bladder cancer-induced animals, and simultaneously, studied the possible therapeutic 
effect of the natural compound DMAPT to counteract the muscle wasting process.  
In healthy animals, the acute administration of cisplatin (10 mg.kg-1 at day zero) did 
not cause a reduction on the body weight nor gastrocnemius muscle weight (Table 1). 
These results suggest that an acute administration of cisplatin cannot induce body wasting, 
contrarily to the decrease on the body and muscle weights reported on healthy animals 
administered with 1 or 3 mg.kg-1 of the drug daily for three or four days, respectively. [10,13] 
Furthermore, urothelial carcinoma did not induce per se muscle wasting (Table 2). However, 
when cisplatin was administered 4.0 mg.kg-1 weekly for 6 weeks to tumour-bearing animals 
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the wasting syndrome occurred (Table 2). Thus, we can hypothesize that: i) chronic rather 
than acute cisplatin exposure seems to be necessary for inducing muscle wasting; ii) cancer 
and cisplatin possible have synergetic effects that, in overall, may cause a wasting process, 
visible on body and gastrocnemius muscle weights. Indeed, results of a study conducted 
by Rafael and collaborators [11] suggested the activation of mutual signalling pathways by 
both cancer and chemotherapy, leading to muscle wasting. Interestingly, only IL-6 appears 
to be involved in the cisplatin-induced wasting process in the context of cancer, since no 
differences were observed in the levels of the others inflammatory mediators studied (Figure 
10). However, other cytokines, such as TNF-α and IL-1β, may be involved in the 
development of the condition. [54,115,116] Since in study 1 the levels of IL-6 in serum did 
not suffer any alteration with cisplatin administration (Figure 5), it can be suggested that this 
cytokine might have origin in tumour cells or in the immune response associated. Indeed, 
the primary sources of IL-6 are the tumour cells and immune cells, such as tumour-
associated macrophages (TAM). [117]  Interestingly, cisplatin caused a decrease in the 
spleen weight on urothelial-carcinoma-bearing animals (Table 2). Indeed, one study 
demonstrated that cisplatin may have adverse effects on the spleen, damaging its 
architecture, and therefore, decreasing its weight. [118] However, in healthy animals, did 
not occurred an increase in the spleen weight after cisplatin administration (Table 1) and 
any alteration in the serum levels of the inflammatory mediators studied (Figure 5) was 
observed, which is indicative of an absence of an inflammatory state, supporting the idea 
that no cachectic syndrome was developed. Furthermore, the absence of an enhanced 
proteolytic activity of the muscle-specific E3 ligases MuRF1 and MAFbx/atrogin-1 on the 
muscle (Figure 8) validates, at least, that acute administration of cisplatin, in healthy 
animals, does not induce a wasting effect. As suggested by Cloé and collaborators [119], 
the muscle mitochondria may be the place of energy wasting (diminution in ATP production 
efficiency) in cancer cachexia. So, the levels of ATP synthase, on whole gastrocnemius 
muscle, were evaluated and no differences were observed (Figure 6), which corroborates 
the nonexistence of a cachexia syndrome induced by a single dose of cisplatin in healthy 
animals. Cisplatin had an efficient chemotherapeutic function, since when only cisplatin was 
administered to BBN-animals, their body weight decreased comparatively with the BBN 
littermates (Table 2), possibly as a result of the diminution of the tumour size. This 
assumption can be corroborated with the decreased percentage of invasive and muscle 
invasive lesions in the cisplatin group (Table 3). In future work it will be important to analyse 
the cancer and cancer plus cisplatin-induced gastrocnemius muscle remodelling in order to 
view its anabolic/catabolic balance and to complete and confirm, or not, these results.  
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The natural compound DMAPT is currently target of several studies, because of its 
anti-inflammatory effect through the inhibition of NF-κB signalling. [120] Indeed, the 
increased gastrocnemius-to-body weight ratio observed in mice treated with cisplatin plus 
DMAPT, suggestive of hypertrophy (Table 1), might be due to the anti-inflammatory effect 
of this compound. These facts are corroborated by the levels of the acute-phase protein 
CRP (Figure 4), which may reflect the pro-inflammatory cytokine activity. [121] This 
molecule is a biomarker of inflammatory states and in the cisplatin plus DMAPT group its 
levels are decreased, which supports a decrease of inflammation. [122] It is also known that 
an increased expression of MMPs is presented in several inflammatory states, and so, the 
decrease of its levels on the muscle of cisplatin plus DMAPT animals comparatively to the 
cisplatin littermates (Figure 8) supports the previous. [123] Data concerning kidney weight 
(Table 1) might also support this hypothesis. An increase of kidney weight was observed 
on cisplatin-treated animals, which is indicative of cisplatin-induced renal damage. Indeed, 
nephrotoxicity is the principal dose-limiting toxicity of cisplatin, where occurs an 
accumulation of metabolites that cause direct inflammation. [124] Furthermore, Dilek and 
collaborators [125] observed edema in the kidneys of rats treated with cisplatin. Knowing 
that DMAPT can act as an anti-inflammatory agent, we can speculate that the reduction on 
the body weight is derived from a reduction of the inflammatory state and of the edema, 
leading to a body weight close to the control ones. [126] Regarding the spleen, cisplatin 
plus DMAPT decreased its weight (Table 1) that is consistent with a decrease in the splenic 
inflammatory responses. [127] In fact, cisplatin increases the splenic tissue expression of 
the pro-inflammatory cytokines TNF-α, IL-6 and IL-1β and DMAPT in combination with the 
chemotherapeutic agent gemcitabine is capable of reducing the levels of these cytokines. 
[97,118] However, it seems that IL-6 does not play a fundamental role to the hypertrophy 
observed in the muscle of the animals treated with the combination of cisplatin and DMAPT, 
since the levels of this cytokine are similar between all the three groups. 
Curiously, our results suggest that the combination of cisplatin plus DMAPT may 
induce the formation of p50 homodimers in the gastrocnemius muscle through the 
overexpression of TWEAK (Figure 7) and does not have an effect on the p65 subunit or 
IκBα. Indeed, TWEAK can activate the NF-κB pathway. [128] Comparing these results with 
other studies it was expected that wasting occurred, but interestingly, and as said before, 
the animals of this group seem to have developed hypertrophy, which should be confirmed 
by morphometric analysis of muscle sections. [13,129] Several cellular processes are 
regulated by the ubiquitously expressed factor NF-κB, including immune response, cellular 
survival, proliferation and differentiation. [130] Furthermore, it can be activated by numerous 
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extracellular signals, which emphasizes the complexity of its regulation and function. In 
addition, skeletal muscle development is a multistep process in which every stage is both 
positive and negatively regulated by mechanisms triggered by environmental stimulus, 
adding even more complexity to the skeletal muscle remodelling process mediated by NF-
κB. [131] The majority of the studies regarding skeletal muscle injury refers that 
inflammation is linked to atrophy. [132] Nevertheless, this fact is not that straightforward, 
because of the closely relation between the regeneration of the skeletal myotubes and the 
inflammatory process. After an injury in the skeletal muscle, several types of cells, including 
macrophages, neutrophils and monocytes infiltrate into the damaged area. Simultaneously, 
satellite cells differentiate into transient-amplifying myoblasts that proliferate, fuse with one 
another and regenerate skeletal myotubes. Therefore, it is reasonable to presume that 
some mediators expressed during the inflammatory process may have an impact on 
skeletal muscle regeneration. Unfortunately, the exact mechanisms are unknown. [132] In 
this study, it seems that cisplatin plus DMAPT reduced the inflammation, and so, other pro-
inflammatory cytokines besides the ones studied may be involved in this association 
between NF-κB, inflammation and hypertrophy. Another hypothesis is the association of the 
NF-κB pathway with the p38 MAPK one, since this cross-talk has been related with the 
control of the myogenic progression. [131] On one hand, the p38 MAPK pathway positively 
regulates the myogenic differentiation. On the other hand, the role of NF-κB is controversial, 
since both positive and negative effects have been stated. According to several studies, the 
NF-κB pathway is activated in proliferating and differentiating myoblasts and p38 activation 
induces NF-κB transcriptional activity. [131,133,134] It is also suggested by Lee and 
collaborators [135] that Akt, which is activated in response to some cytokines and has 
growth-promoting properties, may activate the NF-κB pathway through IKK and p38, 
stimulating p65 transactivation. [136] Therefore, in future studies it would be important to 
analyse these pathways and their relationship in the context of cancer- and cisplatin-
induced muscle wasting.  
Another positive effect of NF-κB on skeletal muscle is that during myoblast 
differentiation, IGF-2 can induce the NF-κB DNA-binding activity, possibly through a 
mechanism that involves IκBα phosphorylation. [137] There are also some studies 
regarding the occurrence of hypertrophy in the cardiac muscle. For example, upregulation 
of beclin 1 can induce cardiac hypertrophy and it is known that NF-κB positively regulates 
its expression. [138,139] Importantly, parthenolide, which is the sesquiterpene lactone from 
which DMAPT is generated, can increase the levels of beclin 1. [140] Another molecule that 
may be involved is the granulocyte colony-stimulating factor (G-CSF), since it participates 
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in cell differentiation, proliferation and survival and its expression can be induced by NF-κB 
activation. [132,141] This cytokine seems to have a critical role in skeletal myocyte 
regeneration, thus showing the importance of inflammation-mediated induction of muscle 
regeneration. [132] Besides all these studies, evidences of skeletal muscle hypertrophy 
induced by NF-κB activation are poor and in the context of cisplatin and/or DMAPT the 
studies are even lesser. So, we can only speculate that the combination of cisplatin and 
DMAPT, in healthy animals, possibly activates genes related with the differentiation process 
of myoblasts, leading to hypertrophy.  
Since cisplatin in combination with DMAPT caused wasting on gastrocnemius of 
BBN animals (Table 2) suggests that DMAPT does not have protective effects on muscle 
when administered with cisplatin in cancer context. Nevertheless, it seems that DMAPT 
enhances the antitumoural activity of cisplatin, since no animals evidenced invasive and 
muscle invasive lesions (Table 3). Indeed, DMAPT showed anti-proliferative activity in 
tobacco-associated tumours. [142] Furthermore, it was ascertained in a study that DMAPT 
has cytotoxic effects towards breast cancer stem-like cells. [143] The natural compound 
DMAPT seems to be effective in reducing the inflammatory state induced by the tumour 
when combined with cisplatin, which can be observed by the spleen weight and the spleen-
to-body weight ratio (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
VI. CONCLUSION AND  
FUTURE PERSPECTIVES 
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Overall, an acute administration of cisplatin, in healthy animals, appears to be 
incapable of induce a cachectic syndrome. Nevertheless, 15 days of DMAPT administration 
seems to induce muscle hypertrophy through the modulation of the inflammatory process 
and the TWEAK/NF-κB axis. However, when cancer is involved, cisplatin induces muscle 
wasting and DMAPT looks unable of reverting or ameliorating this process, despite its ability 
to reduce the inflammation, which in turn has an important role in the development of 
cachexia. 
The mechanisms behind the muscle wasting process induced by chemotherapy are 
still to be understood, and unfortunately, few studies have been addressed to this specific 
problem. So, investigations devoted to the comprehension of how different 
chemotherapeutic agents (considering doses and mode of administration) may influence 
the loss of skeletal muscle mass are needed. Furthermore and in concordance with the 
results obtained in the present dissertation, it is important to ascertain the specific relation 
between the pathways activated by cancer itself and the ones induced by the anti-cancer 
drugs, and then the combination of both. 
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